<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Alzheimer Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Alzheimer Res</journal-id>
<journal-id journal-id-type="publisher-id">CAR</journal-id>
<journal-title-group>
<journal-title>Current Alzheimer Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1567-2050</issn>
<issn pub-type="epub">1875-5828</issn>
<publisher>
<publisher-name>Bentham Science Publishers</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27137218</article-id>
<article-id pub-id-type="pmc">5070416</article-id>
<article-id pub-id-type="publisher-id">CAR-13-1145</article-id>
<article-id pub-id-type="doi">10.2174/1567205013666160502123607</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Van Dam</surname>
<given-names>Debby</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vermeiren</surname>
<given-names>Yannick</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dekker</surname>
<given-names>Alain D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naudé</surname>
<given-names>Petrus J.W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Deyn</surname>
<given-names>Peter P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="aff1"><label>1</label>
Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, <country>Belgium</country>;</aff>
<aff id="aff2"><label>2</label>Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, <country>The Netherlands</country>;</aff>
<aff id="aff3"><label>3</label>Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp <country>Belgium</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Address correspondence to this author at the Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, and, Faculty of Medical and Health Care Sciences, University of Antwerp, Universiteitsplein 1, BE-2610 Wilrijk (Antwerp), Belgium; Tel: +32 32652620; Fax: +32 32652618;, E-mails: <email xlink:href="peter.dedeyn@uantwerpen.be">peter.dedeyn@uantwerpen.be</email>, <email xlink:href="dedeyn@skynet.be">dedeyn@skynet.be</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<month>10</month>
<year>2016</year>
</pub-date>
<volume>13</volume>
<issue>10</issue>
<fpage>1145</fpage>
<lpage>1164</lpage>
<permissions>
<copyright-statement>© 2016 Bentham Science Publishers</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">
<license-p>
This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (
<uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode" xlink:type="simple">
https://creativecommons.org/licenses/by-nc/4.0/legalcode
</uri>
), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
</license-p>
</license>
</permissions>
<abstract>
<p>Neuropsychiatric symptoms (NPS) are an integral part of the dementia syndrome and were therefore recently included in the core diagnostic criteria of dementia. The near universal prevalence of NPS in Alzheimer’s disease (AD), combined with their disabling effects on patients and caregivers, is contrasted by the fact that few effective and safe treatments exist, which is in part to be attributed to our incomplete understanding of the neurobiology of NPS. In this review, we describe the pathological alterations typical for AD, including spreading and evolution of burden, effect on the molecular and cellular integrity, functional consequences and atrophy of NPS-relevant brain regions and circuits in correlation with specific NPS assessments. It is thereby clearly established that NPS are fundamental expressions of the underlying neurodegenerative brain disease and not simply reflect the patients’ secondary response to their illness. Neuropathological studies, moreover, include a majority of end-stage patient samples, which may not correctly represent the pathophysiological environment responsible for particular NPS that may already be present in an early stage, or even prior to AD diagnosis. The burdensome nature and high prevalence of NPS, in combination with the absence of effective and safe pharmacotherapies, provide a strong incentive to continue neuropathological and neurochemical, as well as imaging and other relevant approaches to further improve our apprehension of the neurobiology of NPS.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>Aggression</kwd>
<kwd>amyloid</kwd>
<kwd>depression</kwd>
<kwd>neurofibrillary tangles</kwd>
<kwd>neuronal loss</kwd>
<kwd>psychosis</kwd>
<kwd>neurotransmitter</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>INTRODUCTION</title>
<p>As the prototype of cortical dementias, Alzheimer’s disease (AD) presents with prominent cognitive deficits in several domains, including episodic and semantic memory, executive and attentional processing, as well as visuospatial functioning [<xref ref-type="bibr" rid="R1">1</xref>], which have been intensely studied for many decades. In addition to the declining cognitive function, AD and related dementias are equally associated with a high prevalence of behavioral and psychiatric disturbances [<xref ref-type="bibr" rid="R2">2</xref>], consisting of depression, apathy, agitation, aggression, sleep disorders, delusions and hallucinations (psychosis), activity disturbances, anxieties/phobias, irritability, disinhibition and euphoria/dysphoria [<xref ref-type="bibr" rid="R3">3</xref>-<xref ref-type="bibr" rid="R7">7</xref>]. Originally labelled as behavioral and psychological signs and symptoms of dementia (BPSD) [<xref ref-type="bibr" rid="R8">8</xref>], these symptoms have more recently also been clustered under the umbrella term of neuropsychiatric symptoms (NPS) [<xref ref-type="bibr" rid="R7">7</xref>].</p>
<p>NPS are an integral part of the dementia syndrome and affect the majority of all dementia subjects over the course of their illness [<xref ref-type="bibr" rid="R9">9</xref>]. NPS have an important impact on patients, caregivers/relatives, and society at large. They impact patients’ functioning and often cause premature transition to structured living environments and institutionalization [<xref ref-type="bibr" rid="R10">10</xref>]. Since they are often more difficult to cope with than cognitive changes, they imply a major burden to family members and health care professionals [<xref ref-type="bibr" rid="R11">11</xref>]. Moreover, NPS have been linked to accelerated cognitive decline [<xref ref-type="bibr" rid="R12">12</xref>], increased risk of secondary morbidity or injury [<xref ref-type="bibr" rid="R13">13</xref>], as well as greater risk of mortality [<xref ref-type="bibr" rid="R10">10</xref>]. Altogether, NPS are a major cause of diminished quality of life for both patients and caregivers and contribute significantly to the overall costs of dementia care [<xref ref-type="bibr" rid="R14">14</xref>].</p>
<p>Despite being almost universally present during the course of dementia, only in the recently published fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM), NPS have finally been recognized as an integral part of the disease process, and, moreover, have been included in the core diagnostic criteria of dementia, referred to as ‘major or mild neurocognitive disorder (NCD)’ [<xref ref-type="bibr" rid="R15">15</xref>]. DSM-V criteria circumscribe NPS as ‘specifiers’, <italic>i.e.</italic> psychotic features, mood disturbances (depression, anxiety, and elation), agitation, apathy, disinhibition, sleep disturbances, hyperphagia and hoarding. Furthermore, in the additional description of ‘major or mild NCD due to Alzheimer’s disease’, depression and apathy in the earliest stages of AD, together with psychotic features, irritability, agitation, combativeness, and wandering in the advanced stages of the disease, are all classified as ‘associated features supporting the diagnosis’ [<xref ref-type="bibr" rid="R15">15</xref>], thereby at last rightly acknowledging the importance of NPS in dementia diagnosis.</p>
<p>Given that up to 80-97% of AD patients in the general population may suffer from NPS at some point during their disease course [<xref ref-type="bibr" rid="R16">16</xref>], this near universal prevalence of NPS in AD, combined with their serious and disabling effects on patients and caregivers, has recently focused significant attention on the fact that few effective and safe treatments exist, which can – at least partially – be attributed to our incomplete comprehension of the neurobiology of NPS. This paper will describe the pathological alterations typical for AD, including spreading and evolution of burden, effect on the molecular and cellular integrity, functional consequences and atrophy of NPS-relevant brain regions and related circuits. Although the main focus will be on human studies, also a few relevant animal model approaches will be discussed. The development and phenotyping of animal models is indeed essential in AD-related research as valid models enable the appraisal of early pathological processes – which are often not or poorly accessible in patients [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>].</p>
</sec>
<sec>
<label>2.</label>
<title>Neuropathological Features of AD</title>
<p>The neuropathological hallmarks of AD include “positive” lesions such as amyloid plaques, cerebral amyloid angiopathy, neurofibrillary tangles, and neuroinflammatory responses, and “negative” lesions, such as neuronal and synaptic dysfunction and loss.</p>
<sec>
<label>2.1.</label>
<title>Amyloid-Related Pathology</title>
<p>One of the major positive hallmarks of both familial and late-onset AD is the extracellular accumulation of amyloid-β (Aβ) peptides in amyloid or senile plaques (SP). Aβ is a 36-43 amino acid fragment of the transmembrane and extracellular domains of the amyloid precursor protein (APP) [<xref ref-type="bibr" rid="R19">19</xref>]. The APP amyloidogenic pathway is responsible for producing Aβ, and involves the cleavage of APP by β-secretase, followed by γ-secretase. The non-amyloidogenic pathway, in which APP is first cleaved by α-secretase, results in a neuroprotective sAPPα fragment. Although the excessive aggregation and deposition of Aβ has been reported to cause neurodegeneration in AD, the amyloidogenic pathway is a physiological process important for normal neuronal functioning [<xref ref-type="bibr" rid="R20">20</xref>], especially as modulator of synaptic plasticity in its monomeric form [<xref ref-type="bibr" rid="R21">21</xref>]. Aβ is characterized by the intrinsic tendency to form aggregates that are referred to as oligomers, protofibrils or mature amyloid fibrils, depending on their appearance in electron and atomic force microscopy [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>]. Aβ1-40 and Aβ1-42 are the most common types with the more hydrophobic Aβ1-42 being particularly prone to aggregation [<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R25">25</xref>]. Although typically Aβ plaques are classified into diffuse, dense-core and neuritic plaques, based on their morphology and positive or negative staining with Thioflavin-S or Congo Red, they exist as a continuum in which complex mixtures of fibrillar, granular, and even soluble Aβ forms are associated with highly varying degrees of surrounding glial and neuritic alterations [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>].</p>
<p>Although some have reported that the insoluble form of Aβ is the major variant causing AD pathology [<xref ref-type="bibr" rid="R28">28</xref>], others state that both insoluble and soluble forms are observed in symptomatic AD patients, as well as in presymptomatic cases [<xref ref-type="bibr" rid="R29">29</xref>]. In this respect, several lines of investigation now support the view that increased levels of soluble Aβ1-42 oligomers might lead to synaptic damage, neurodegeneration, and, accompanying memory loss, mainly by inhibiting long-term potentiation, damaging spines and interfering with activity-regulated cytoskeleton associated protein distribution [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R30">30</xref>].</p>
<p>Familial forms of AD can be caused by mutations in <italic>APP</italic> on chromosome 21 [<xref ref-type="bibr" rid="R31">31</xref>]. The greater part of these mutations are located at the secretase cleavage sites, or the transmembrane domain of APP. Mutations near the β- and γ-secretase cleavage sites have been reported to lead to an overproduction of total Aβ, or an increased Aβ1-42/Aβ1-40 ratio. Furthermore, mutations within Aβ are hypothesized to increase its tendency to form aggregates [<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref>]. Since presenilin (PSEN)-1 and PSEN2 proteins constitute the active site of γ-secretase [<xref ref-type="bibr" rid="R34">34</xref>], mutations in their coding genes (PSEN1 and PSEN2) result in a deficient γ-secretase and can also lead to AD pathology [<xref ref-type="bibr" rid="R35">35</xref>]. In fact, most familial AD cases are attributed to mutations in PSEN1 or PSEN2 [<xref ref-type="bibr" rid="R34">34</xref>]. Of interest to note here is Down syndrome (DS) considered a human overexpression model of AD based on trisomy of chromosome 21 which harbors the <italic>APP</italic> gene [<xref ref-type="bibr" rid="R36">36</xref>]. In addition to the congenital intellectual disability, DS is associated with accelerated ageing, including a significantly increased risk of developing early-onset AD; approximately 50-70% of DS individuals develop AD by the age of 60-70 years [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>]. Trisomy of <italic>APP</italic> is likely to make a significant contribution to the increased frequency of dementia in people with DS, although other genes than <italic>APP</italic> located on chromosome 21 may also contribute to the early onset of AD in DS [<xref ref-type="bibr" rid="R39">39</xref>].</p>
<p>Regarding sporadic AD, the apolipoprotein E (APOE) ε4 allele is believed to account for most of the genetic risk, but as a susceptibility gene it is neither necessary nor sufficient to cause late-onset AD [<xref ref-type="bibr" rid="R40">40</xref>]. APOE is a cholesterol transporter in the brain, and is essential for deposition and fibrillization of Aβ and plaque formation [<xref ref-type="bibr" rid="R41">41</xref>].</p>
<sec>
<label>2.1.1.</label>
<title>Amyloid Cascade Hypothesis</title>
<p>It is widely assumed that the neuropathology of AD is initiated by abnormal aggregation and deposition of Aβ peptide, either due to increased Aβ production or decreased Aβ clearance. The aggregation and deposition of Aβ are hypothesized to subsequently cause neuronal damage and dementia. This theory is generally known as the amyloid cascade hypothesis, and is supported by several lines of evidence [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R42">42</xref>]. Firstly, the discovery that presenilin 1 and 2 (PSEN1 and PSEN2) enhance the processing of APP to amyloidogenic Aβ, through a direct effect on γ-secretase, is a first indication [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>]. Secondly, mutations in the gene encoding tau protein cause frontotemporal lobar degeneration with parkinsonism [<xref ref-type="bibr" rid="R45">45</xref>]. This dementia subtype is characterized by a severe deposition of abnormal tau in the brain, while no Aβ inclusions can be found. This indicates that severe alterations in tau metabolism are not able to induce amyloid pathology. Therefore, it was considered that neurofibrillary tangles (NFTs, see 2.2) in AD only appeared after the occurrence of amyloid pathology, rather than before [<xref ref-type="bibr" rid="R35">35</xref>]. A third indication supporting the amyloid cascade hypothesis is that transgenic mice overexpressing mutant human APP and human tau, show increased NFT formation compared to mice overexpressing tau alone. Moreover, the number and structure of SP remained unaltered [<xref ref-type="bibr" rid="R46">46</xref>], suggesting that modified APP processing occurs before the appearance of NFT [<xref ref-type="bibr" rid="R35">35</xref>]. Fourthly, overexpression of chromosome 21-located genes in DS is associated with an increased risk of developing AD, neuropathologically associated with extensive deposition of Aβ plaques, as well as neuroinflammation and substantial NFTs (Wisniewski <italic>et al.</italic>, 1985), whereas other types of dementia, for example frontotemporal or Parkinson’s disease dementia are not observed within this population [<xref ref-type="bibr" rid="R47">47</xref>].</p>
<p>However, observations by other research groups do not comply easily with the amyloid cascade hypothesis. It has been reported, for instance, that amyloid burden does not correlate with the severity and duration of the dementia syndrome, whereas several other clinicopathological studies confirmed that the amount and distribution of NFT indeed correlated with the severity and duration of the disease [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R48">48</xref>]. The amyloid hypothesis therefore remains a debatable theory until present [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R49">49</xref>]. Moreover, despite plaque pathology being present in virtually all DS individuals aged &gt;40 years [<xref ref-type="bibr" rid="R50">50</xref>] and increased Aβ expression, 30-50% of DS subjects will never develop clinical AD [<xref ref-type="bibr" rid="R51">51</xref>], implying indeed that the amyloid cascade theory may not fully cover AD etiology.</p>
</sec>
<sec>
<label>2.1.2.</label>
<title>Topographic Distribution of Amyloid Pathology</title>
<p>As illustrated by (Fig. <bold><xref ref-type="fig" rid="F1">1A</xref></bold>), amyloid plaques mainly accumulate in the neocortex, but with a poorer predictability as opposed to NFT spreading. Amyloid deposits involve all six layers of the neocortex, even though layers I and VI are less affected than layers II-V [<xref ref-type="bibr" rid="R53">53</xref>]. In advanced AD cases, lesions can even be detected in the transitional area of cortical layer VI with the adjacent white matter. In general, two overall staging systems have been proposed. Firstly, Braak and Braak [<xref ref-type="bibr" rid="R54">54</xref>] distinguished three stages: stage A, with amyloid deposits preferentially in the basal portions of frontal, temporal and occipital lobes; stage B, in which all neocortical association areas are affected, except for the primary sensory, motor and visual cortices, and with only mild lesions in the hippocampus; and stage C, characterized by additional plaque formation in these primary neocortical areas, and sometimes amyloid deposits in the molecular layer of the cerebellum and several subcortical nuclei, such as striatum and thalamus among others. Secondly, Thal <italic>et al</italic>. [<xref ref-type="bibr" rid="R55">55</xref>] proposed five stages: stage 1 or the neocortical stage; stage 2, with additional depositions in the entorhinal cortex, hippocampal formation, amygdala, and, insular and cingulated cortices; stage 3, with extra lesions in subcortical nuclei, such as basal forebrain cholinergic nuclei, thalamus, and, even white matter; stage 4, characterized by involvement of brainstem structures, such as substantia nigra and colliculi; and, finally, stage 5, where amyloid deposits are localized in the pons (raphe nuclei and locus coeruleus e.g.) and molecular layer of the cerebellum as well.</p>
<p>Recently, Aβ deposit staging as measured according to the phases of deposition described by Thal <italic>et al.</italic> [<xref ref-type="bibr" rid="R55">55</xref>] have been implemented by Montine <italic>et al.</italic> [<xref ref-type="bibr" rid="R56">56</xref>] into an overall “ABC scoring” approach, which includes Aβ plaque scoring (A score), as well as Braak NFT staging (B score; see section 2.2 Tau-related pathology) and neuritic plaque scoring (C score). The five stages of Aβ plaque scoring [<xref ref-type="bibr" rid="R55">55</xref>] have been translated into the A score as follows: A score 0 = stage 0; A score 1 = stage 1 or 2; A score 2 = stage 3; A score 3 = stage 4 or 5.</p>
</sec>
</sec>
<sec>
<label>2.2.</label>
<title>Tau-Related Pathology</title>
<p>NFT consist of abnormally paired fibrils that are wound around each other, also referred to as paired helical fragments. The major component of NFT is hyperphosphorylated microtubule-associated protein tau (MAPT), although other proteins, such as ubiquitin [<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R58">58</xref>] and cholinesterases [<xref ref-type="bibr" rid="R59">59</xref>] might also be present. MAPT is an axonal protein binding to microtubules, hereby promoting microtubule assembly and stability [<xref ref-type="bibr" rid="R34">34</xref>]. Tau hyperphosphorylation in AD is initiated intracellularly and causes sequestration of tau and other microtubule-associated proteins. This, in turn, results in impaired axonal transport by disassembly of the microtubules, and impaired neuronal and synaptic function [<xref ref-type="bibr" rid="R60">60</xref>]. Moreover, aggregation of hyperphosphorylated tau into fibrils further hampers neuronal functioning. The distribution and extent of NFT in the brain of AD patients is associated with the severity and duration of the disease [<xref ref-type="bibr" rid="R48">48</xref>], suggesting that these lesions have a direct impact on neuronal functioning [<xref ref-type="bibr" rid="R58">58</xref>]. In the early stages, NFT are observed in the transentorhinal cortex, while in following stages, NFT further spread to the amygdala and hippocampus. As the disease progresses, NFT can also be found in neocortical association areas [<xref ref-type="bibr" rid="R61">61</xref>].</p>
<p>Three morphological stages have been defined: (1) pre- or diffuse NFT within the cytoplasm with well-preserved dendrites and a centered nucleus; (2) mature or fibrillary intraneuronal NFT consisting of cytoplasmatic filamentous tau aggregates causing displacement of the nucleus towards the periphery of the soma and distorted dendritic segments (neuropil threads); and (3) extraneuronal ‘ghost’ NFTs as a result of death of tangle-bearing neurons [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R62">62</xref>].</p>
<p>The combination of the intracellular location of tau aggregates with the diverse ultrastructural conformations, based on the (combination of) different isoforms and various possible posttranslational modifications, as well as colocalization with other β-sheet structured protein deposits, complicates the development of ligands for tau imaging. Nevertheless, several selective tau radiotracers have been developed, but still lack the more widespread clinical application of Pittsburgh compound-B [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R64">64</xref>].</p>
<sec>
<label>2.2.1.</label>
<title>Topographic Distribution</title>
<p>NFT accumulation starts in the allocortex of the medial temporal lobe (<italic>i.e.</italic> entorhinal cortex and hippocampus) and spreads to the associative isocortex, relatively sparing the primary sensory, motor, and visual areas (Fig. <bold>1B</bold>). In total, Braak and Braak [<xref ref-type="bibr" rid="R55">55</xref>] distinguished six stages (I-VI).</p>
<p>In stage I, NFT appear consistently in the (trans)entorhinal cortex, along with the CA1 region of the hippocampus in stage II. Thereafter, limbic structures become affected, such as the subiculum of the hippocampal formation (stage III), the amygdala, thalamus, and, claustrum (stage IV). Finally, NFT spread to virtually all isocortical areas (isocortical stage), with the associative areas being affected prior and more severely (stage V) than the primary sensory, motor, and visual areas (stage VI). Notably, NFT lesions in striatum and substantia nigra might occur during the late isocortical stage. The stellate neurons of layer II, the superficial portion of layer III, and, the large multipolar neurons of layer IV of the entorhinal cortex are preferentially lesioned, whereas the same applies to mainly layers III and V of the isocortical areas [<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R54">54</xref>]. As mentioned before, the Braak staging approach of NFT in AD brain has recently been included in the overall “ABC” scoring consensus of Montine <italic>et al</italic>. [<xref ref-type="bibr" rid="R56">56</xref>]. The NFT-based B score refers to the Braak staging as follows: B score 0 = stage 0; B score 1 = stage I or II; B score 2 = stage III or IV and B score 3 = stage V or VI.</p>
</sec>
</sec>
<sec>
<label>2.3.</label>
<title>Other Protein Inclusions</title>
<p>The misfolding, aggregation and accumulation of proteins in the brain, resulting in synaptic dysfunction and neuronal loss is a seminal pathological mechanism in diverse neurodegenerative diseases [<xref ref-type="bibr" rid="R65">65</xref>]. Although the distribution and composition of prion-like protein aggregates are considered different in each neurodegenerative disease [<xref ref-type="bibr" rid="R65">65</xref>], AD brain may also contain other types of protein deposits besides amyloid plaques and NFT. More than 50% of AD patients also exhibit abundant accumulation of α-synuclein (α-Syn)-positive Lewy bodies [<xref ref-type="bibr" rid="R66">66</xref>] and are termed the Lewy body variant of AD, which typically exhibits an accelerated disease course and a more pronounced cognitive decline than pure AD patients [<xref ref-type="bibr" rid="R67">67</xref>, <xref ref-type="bibr" rid="R68">68</xref>]. It has been hypothesized that Aβ and a-Syn can interact synergistically thereby accelerating the pathology and cognitive decline [<xref ref-type="bibr" rid="R69">69</xref>], although it has also been postulated that a-Syn can be neuroprotective against Aβ-induced cell death, suggesting a cell defense mechanism during the initial stages of the mixed pathology [<xref ref-type="bibr" rid="R70">70</xref>].</p>
<p>The dominantly inherited polyglutamine (polyQ) diseases, such as Huntington disease and spinocerebellar ataxias, are caused by unstable trinucleotide repeat expansions, leading to pathogenic glutamine tracts in particular proteins [<xref ref-type="bibr" rid="R71">71</xref>]. Expansions within the polyQ tract of the TATA box-binding protein (TBP), an essential transcription factor, result in accumulation of the protein in various polyQ diseases. A CAG/CAA repeat expansion in the TBP gene, for example, may cause spinocerebellar ataxia with associated features such as dementia and/or psychiatric manifestations [<xref ref-type="bibr" rid="R72">72</xref>]. Also in AD brain, TBP accumulation has been observed within NFT structures, with variable levels between patients, across brain areas and relative to tau and Aβ [<xref ref-type="bibr" rid="R73">73</xref>].</p>
<p>Patients with amyotrophic lateral sclerosis have aggregates mainly composed of superoxide dismutase 1 (SOD1) in cell bodies and axons of motor neurons [<xref ref-type="bibr" rid="R74">74</xref>]. SOD1, a ubiquitously expressed antioxidant enzyme that plays a key role in the cellular defense against harmful superoxide radicals, is however also a major target of oxidative damage in AD which forms proteinaceous aggregates that are associated with amyloid SP and NFTs in AD brains [<xref ref-type="bibr" rid="R75">75</xref>].</p>
<p>The ubiquitin proteasome system (UPS) is a highly regulated mechanism of intracellular protein degradation and turnover and thus plays a role in a variety of cellular functions. Dysregulated ubiquitination and protein clearance has been implicated in various neurodegenerative disorders, including AD [<xref ref-type="bibr" rid="R76">76</xref>]. Ubiquitinated forms of tau and Aβ, as well as other ubiquitinated proteins, are major components of the AD-typical protein aggregates [<xref ref-type="bibr" rid="R77">77</xref>-<xref ref-type="bibr" rid="R79">79</xref>]. Components of the UPS could be linked to the early phase of AD, marked by synaptic dysfunction, as well as to the late stages of the disease, characterized by neurodegeneration [<xref ref-type="bibr" rid="R78">78</xref>, <xref ref-type="bibr" rid="R79">79</xref>].</p>
<p>Initially, transactivation responsive region (TAR)-DNA-binding protein 43 (TDP-43) was considered to be a disease-specific component of ubiquitin-positive and tau-negative inclusions in the brains of patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions and amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="R80">80</xref>]. However, it is now widely known that this protein can also abnormally concomitantly accumulate in other neurodegenerative diseases, including AD with a prevalence of approximately 30%, variable distribution patterns and a modified clinicopathologic and radiologic AD phenotype [<xref ref-type="bibr" rid="R81">81</xref>-<xref ref-type="bibr" rid="R83">83</xref>]. TDP-43 pathology is thought to be triggered by Aβ, independent of tau [<xref ref-type="bibr" rid="R84">84</xref>].</p>
</sec>
<sec>
<label>2.4.</label>
<title>Neuroinflammation</title>
<p>Clinical manifestations preceding the dementia stage support an early and substantial involvement of an innate neuroimmune response in AD pathogenesis [<xref ref-type="bibr" rid="R85">85</xref>-<xref ref-type="bibr" rid="R87">87</xref>]. The two major inflammation-related cellular players are microglia and astrocytes. Microglia have crucial physiological functions in the brain, including tissue surveillance and synaptic remodeling [<xref ref-type="bibr" rid="R88">88</xref>], which may be compromised by Aβ species inducing a dystrophic microglia phenotype, reducing phagocytic capacity, and eliciting an increased cytokine production [<xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R90">90</xref>]. Analogously, since the physiological role of astrocytes has been linked to fluid, ion, pH, and transmitter homeostasis, synapse function, regulation of blood flow and energy and metabolism, astrocytic atrophy leading to a detriment of neuronal support may play a role in AD-related symptomatology [<xref ref-type="bibr" rid="R87">87</xref>, <xref ref-type="bibr" rid="R91">91</xref>]. Initially, the acute inflammatory response is thought to aid clearance and restore tissue homeostasis. Triggers (e.g. pathological ageing with sustained exposure to Aβ, genetic mutations) and aggravators (e.g. peripheral inflammation, obesity, brain trauma) promote sustained immune activation, which ultimately leads to chronic neuroinflammation. Pathological accumulation of Aβ is considered a key player in the activation of microglia and astrocytes in AD brain that leads to the upregulation of a myriad of mediators and modulators of neuroinflammation [<xref ref-type="bibr" rid="R87">87</xref>, <xref ref-type="bibr" rid="R92">92</xref>]. These include among others, cytokines [<xref ref-type="bibr" rid="R92">92</xref>], adhesion molecules and chemokines [<xref ref-type="bibr" rid="R93">93</xref>, <xref ref-type="bibr" rid="R94">94</xref>], caspases [<xref ref-type="bibr" rid="R95">95</xref>], prostaglandins [<xref ref-type="bibr" rid="R96">96</xref>], complement system components [<xref ref-type="bibr" rid="R97">97</xref>], nitric oxide and reactive oxygen species [<xref ref-type="bibr" rid="R98">98</xref>], and induce alterations to the neurovascular unit [<xref ref-type="bibr" rid="R99">99</xref>], which can be detrimental to neuronal functioning. Perpetuation of glial activation causes functional and structural changes that result in neuronal degeneration and scar formation [<xref ref-type="bibr" rid="R87">87</xref>, <xref ref-type="bibr" rid="R100">100</xref>]. Although neuroinflammation plays a pivotal role in AD pathogenesis, detection of inflammatory markers in CSF, blood or directly in the brain via imaging paradigms, has not yet been established as a valuable and validated diagnostic method and progression monitor [<xref ref-type="bibr" rid="R87">87</xref>], let alone the potential link between neuroinflammation and NPS in AD. Nevertheless, the involvement of (neuro)inflammation in psychiatric disorders [<xref ref-type="bibr" rid="R101">101</xref>] and AD indicates its possible involvement underlying NPS in AD. Therefore, in subsequent sections, relevant studies assessing neuroinflammatory mediators of NPS will be dealt with where relevant.</p>
<p>It has been previously evidenced that dense-core amyloid plaques are commonly associated with reactive astrocytes and microglial cells [<xref ref-type="bibr" rid="R102">102</xref>, <xref ref-type="bibr" rid="R103">103</xref>]. The latter indicates that Aβ might be the major trigger of this response, even though a highly significant positive correlation between both astrocytosis and microgliosis and NFT burden, and not amyloid plaque burden, has been found as well [<xref ref-type="bibr" rid="R104">104</xref>].</p>
</sec>
<sec>
<label>2.5.</label>
<title>Neuronal and Synaptic Loss</title>
<p>The mechanisms underlying AD-related neuronal and synaptic loss are very complex and different in nature. Accumulated Aβ induces multiple cytotoxic effects, such as oxidative stress, changes in ionic homeostasis, alterations in enzymatic kinase activity, and hyperphosphorylation of tau protein. Subsequently, apoptosis, activation of glutamate receptors, DNA damage, and, elevation of intracellular calcium levels may occur [<xref ref-type="bibr" rid="R105">105</xref>-<xref ref-type="bibr" rid="R108">108</xref>]. Eventually, all these Aβ-induced events may directly or indirectly induce neuronal death. However, the quantity of Aβ deposits does not necessarily correlate with clinical features of patients, since SP are also found in the brain of elderly without AD [<xref ref-type="bibr" rid="R109">109</xref>]. In addition, accumulation of SP is not associated with the amount of synaptic loss [<xref ref-type="bibr" rid="R110">110</xref>, <xref ref-type="bibr" rid="R111">111</xref>], nor with clinical disease severity. Moreover, because the spatiotemporal and laminar pattern of synapse loss matches that of neuron loss, and, concurrently, synaptic loss even exceeds the existing neuronal loss within a particular cortical area, it becomes very likely that synapse loss precedes neuronal loss indeed. Probably this is also why synaptic density is the best pathological correlate of cognitive decline in AD [<xref ref-type="bibr" rid="R112">112</xref>-<xref ref-type="bibr" rid="R114">114</xref>]. Synaptic alterations in AD are associated with dendritic pathology [<xref ref-type="bibr" rid="R115">115</xref>, <xref ref-type="bibr" rid="R116">116</xref>]. Dendritic degeneration and loss in AD brain has been described mostly in the perirhinal and entorhinal cortices [<xref ref-type="bibr" rid="R54">54</xref>], in the hippocampus, particularly in the subiculum, where the dendritic arborization index was substantially decreased by up to 66% [<xref ref-type="bibr" rid="R117">117</xref>], as well as in various other cortical areas [<xref ref-type="bibr" rid="R118">118</xref>-<xref ref-type="bibr" rid="R121">121</xref>].</p>
<p>Although neurotoxicity of Aβ has initially been attributed to its fibrillary forms, later studies showed that neurotoxins also comprise small diffusible Aβ oligomers, called Aβ-derived diffusible ligands (also referred to as ADDLs) [<xref ref-type="bibr" rid="R23">23</xref>]. The presence of high-affinity ADDL-binding proteins in hippocampus and frontal cortex, but not cerebellum parallels the regional specificity of AD pathology and suggests the involvement of a toxin receptor-mediated mechanism [<xref ref-type="bibr" rid="R108">108</xref>]. Moreover, posttranslational changes to Aβ peptides <italic>i.e.</italic> nitration, oxidation, phosphorylation, isomerization, pyroglutamylation, racemization, and glycosylation, affects their biochemical properties and functions in the pathophysiology of AD [<xref ref-type="bibr" rid="R122">122</xref>].</p>
</sec>
</sec>
<sec>
<label>3.</label>
<title>Brain circuits, networks and systems involved in regulation of behaviour</title>
<p>The fact that with progression of the disease, AD affects nearly all brain regions, including the epicenters of emotions and cognition and their extensive and reciprocal neuronal connections, forms a logical foundation for the development of both cognitive and NPS-related manifestations. Increasing knowledge in behavioral neuroscience and the neurocircuitry underlying cognitive and various noncognitive functions over the last decades, has founded the basis for the development of theoretical models describing the neurobiological underpinnings of NPS in AD [<xref ref-type="bibr" rid="R2">2</xref>], with the three major models being (i) the frontal-subcortical circuitry [<xref ref-type="bibr" rid="R123">123</xref>, <xref ref-type="bibr" rid="R124">124</xref>]; (ii) cortico-cortical networks [<xref ref-type="bibr" rid="R125">125</xref>], and (iii) the ascending monoaminergic hypothesis [<xref ref-type="bibr" rid="R126">126</xref>].</p>
<sec>
<label>3.1.</label>
<title>Frontal-Subcortical Circuitry</title>
<p>The frontal-subcortical circuitry model is based on Geschwind’s theory of disconnection syndromes stating that these higher function deficits resulted from white matter lesions or lesions of the association cortices, the latter acting as relay stations between primary motor, sensory and limbic areas [<xref ref-type="bibr" rid="R127">127</xref>]. The prototypic structure of all circuits is an origin in the frontal lobes, projection to striatal structures, connections from striatum to globus pallidus and substantia nigra, projections from these two structures to specific thalamic nuclei, and a final link back to the frontal lobe. In addition to a motor and an oculomotor circuit, at least three frontal-subcortical circuits mediate human behavior: (i) the dorsolateral prefrontal circuit mediating planning, organization, and executive function, (ii) the lateral orbitofrontal circuit mediating inhibitory control, and, (iii) the anterior cingulate circuit mediating motivated behavior (Fig. <bold><xref ref-type="fig" rid="F2">2</xref></bold>; [<xref ref-type="bibr" rid="R124">124</xref>]).</p>
</sec>
<sec>
<label>3.2.</label>
<title>Cortico-Cortical Network</title>
<p>The cortico-cortical network model posits that the human brain consists of five partially segregated and partially overlapping large-scale neurocognitive networks: (i) a right hemisphere-dominant spatial awareness network with epicenters in the dorsal posterior parietal cortex, the frontal eye fields and the cingulate region; (ii) a left hemisphere-dominant language network with epicenters in Wernicke’s and Broca’s areas; (iii) a memory-emotion network with epicenters in the hippocampal–entorhinal regions and the amygdaloid complex; (iv) a working memory-executive function network with epicenters in the prefrontal cortex and probably the posterior parietal cortex; (v) a face and object identification network with epicenters in the midtemporal and temporopolar cortices [<xref ref-type="bibr" rid="R125">125</xref>]. These large-scale networks are composed of widely separated and interconnected local networks that address the neurobiological basis of complex cognitive domains.</p>
<p>The functionality of the memory-emotion network is based on the widely distributed but tightly interconnected limbic structures [<xref ref-type="bibr" rid="R125">125</xref>], that were originally described in the first half of the 20<sup>th</sup> century by C. Jakob (1906), J. Papez (1937), P. Yakovlev (1948) and P. MacLean (1949, 1952).</p>
<p>The subcortical limbic structures include the amygdala, mammillary bodies, hypothalamus, specific thalamic nuclei (anterior, intralaminar, and medial dorsal groups) and the ventral striatum (nucleus accumbens). The cortical limbic components can be separated into limbic and paralimbic zones that display increasing anatomical complexity, ranging from the corticoid areas of the amygdaloid complex, substantia innominata, septal and olfactory nuclei, over the allocortex of olfactory and hippocampal regions, up to the paralimbic or mesocortex including the piriform cortex, entorhinal cortex, the parahippocampal cortex on the medial surface of the temporal lobe, and the cingulate cortex [<xref ref-type="bibr" rid="R128">128</xref>].</p>
<p>Based on functional imaging data and insights from neurological disorders associated with limbic pathology, the limbic network model has recently been updated and further divided in (i) the hippocampal-diencephalic and parahippocampal-retrosplenial network dedicated to memory and spatial orientation; (ii) the temporo-amygdala-orbitofrontal network for the integration of visceral sensation and emotion with semantic memory and behaviour; (iii) the default-mode network involved in autobiographical memories and introspective self-directed thinking. Table <bold><xref ref-type="table" rid="T1">1</xref></bold> summarizes the functions of these limbic networks, the stage they become affected in AD and corresponding symptomatology.</p>
</sec>
<sec>
<label>3.3.</label>
<title>The Ascending Monoaminergic Hypothesis</title>
<p>As extensively reviewed by Trillo <italic>et al.</italic> [<xref ref-type="bibr" rid="R126">126</xref>], the ascending monoaminergic system with cell bodies in the brain stem diffusely projecting via long axons to virtually all parts of the brain is involved in many aspects of behavior. For extensive illustration of the different monoaminergic pathways, we refer to the highly detailed first three figures included in the review by Trillo <italic>et al.</italic> [<xref ref-type="bibr" rid="R126">126</xref>].</p>
<p>The ascending dopaminergic system has been classically divided in the nigrostriatal pathway originating in substantia nigra and targeting striatum (caudate-putamen), and the mesolimbic and mesocortical pathways originating in the ventrotegmental area and projecting towards limbic region and cortical regions, respectively. In more detail, the mesencephalic dopaminergic system targets cortical and subcortical structures including the medial and dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, dorsal and median raphe nucleus, tuberomammilary nucleus, nucleus basalis of Meynert, the external segment of the globus pallidus, putamen, caudate nucleus, medial septum, amygdala, entorhinal cortex, and dentate gyrus. The main norepinephrinergic projections arise from neuronal population in the locus coeruleus which widely project to the telencephalon, including the olfactory bulb, hippocampus, amygdala, thalamus, hypothalamus, ventral striatum, basal forebrain (nucleus basalis of Meynert) and various (neo)cortical areas, among which anterior cingulate cortex, orbitofrontal cortex and dorsolateral prefrontal cortex. Finally, ascending serotonergic fibers arise from the raphe nuclei, which target (neo)cortical areas (for example anterior cingulate cortex, orbitofrontal cortex and dorsolateral prefrontal cortex), hippocampus, striatum (caudate nucleus and putamen) and the external segment of the globus pallidus, medial septum, thalamus and hypothalamus, and the tuberomammillary nucleus.</p>
<p>Overall, monoaminergic fiber projections are composed of generally poorly myelinated axons to innervate the extensive forebrain (including the cortex, basal ganglia, thalamus, and amygdala) [<xref ref-type="bibr" rid="R129">129</xref>]. However, in order to innervate a disproportionately high number of neurons, a selected number of monoaminergic cell bodies make use of a particular method of innervation called “volume transmission”, as opposed to standard synaptic innervation or “wire transmission”. According to this theory, monoaminergic neurons are able to induce modulatory and trophic effects on a large number of neighboring cells through diffusion to distant extra-synaptic sites [<xref ref-type="bibr" rid="R129">129</xref>]. By combining wire and volume transmission-based innervation, the monoaminergic system imposes a strong modulatory influence on most of the regions of the brain, and, hence many aspects of behavior [<xref ref-type="bibr" rid="R126">126</xref>]. Moreover, different monoaminergic systems share similar input and output regions and directly project to each other, thereby further substantiating the highly complex and selective modulatory functions of these systems.</p>
</sec>
</sec>
<sec>
<label>4.</label>
<title>Studies linking pathology – NPS</title>
<p>Over time, the AD-affected brain shrinks dramatically due to widespread cell death, affecting consequently nearly all its functions. Whole brain atrophy rates differ among normal aging individuals and those diagnosed with mild cognitive impairment (MCI) and AD [<xref ref-type="bibr" rid="R130">130</xref>]. The spatial pattern of neocortical atrophy associated with normal versus pathologic aging is not uniform and depends on the degree of disease severity (Fig. <bold><xref ref-type="fig" rid="F3">3</xref></bold>) [<xref ref-type="bibr" rid="R131">131</xref>-<xref ref-type="bibr" rid="R134">134</xref>]. Atrophy is not uniform across cortical and subcortical regions (Fig. <bold>3</bold>), nor does it follow a linear trajectory [<xref ref-type="bibr" rid="R135">135</xref>]. The spatial pattern and rate of decline across the spectrum from normal aging to AD is of course paralleled by the development of various cognitive, functional and behavioral symptoms.</p>
<p>The different pathways, circuits and networks involved in the regulation of behavior (as described in section 3) are logically also affected by AD-related pathology and subsequent atrophy, which may underlie the development of cognitive and NPS-related symptomatology.</p>
<p>Various brain regions included in the frontal-subcortical circuits mediating human behavior (section 3.1) may be affected by AD-related pathology leading to disturbances in the associated behavioral domains, <italic>i.e.</italic> planning, organization, and executive function, inhibitory control and motivated behavior (apathy) [<xref ref-type="bibr" rid="R136">136</xref>-<xref ref-type="bibr" rid="R138">138</xref>].</p>
<p>Some structures of the hippocampal-diencephalic and parahippocampal-retrosplenial network (section 3.2) are particularly vulnerable to damage caused by viral infections or alcohol, leading to for example encephalitis or Korsakoff’s syndrome, respectively [<xref ref-type="bibr" rid="R128">128</xref>]. In addition, imaging studies have documented altered metabolism and reduced functional activation of this network also in age-related neurodegenerative disorders such as MCI and early stages of AD [<xref ref-type="bibr" rid="R139">139</xref>, <xref ref-type="bibr" rid="R140">140</xref>], while damage to the temporo-amygdala-orbitofrontal network manifests with cognitive and behavioural symptoms characteristic of for example temporal lobe epilepsy, mood disorders, traumatic brain injury, psychopathy and neurodegenerative dementias, including advanced AD [<xref ref-type="bibr" rid="R128">128</xref>]. Dysfunction of the dorsomedial default-mode network has been related to various neuropsychiatric disorders, including schizophrenia, epilepsy, anxiety and depression, autism, attention deficit/hyperactivity disorder and importantly, also in dementia (including MCI and AD) [<xref ref-type="bibr" rid="R141">141</xref>-<xref ref-type="bibr" rid="R143">143</xref>].</p>
<p>In addition to the cholinergic degeneration in AD [<xref ref-type="bibr" rid="R144">144</xref>], extensive neuropathological studies have established a compelling link between abnormalities in structure and function of subcortical monoaminergic systems and the pathophysiology of AD (for review: [<xref ref-type="bibr" rid="R126">126</xref>, <xref ref-type="bibr" rid="R145">145</xref>]). While the rostral raphe complex is especially susceptible to NFT formation, other monoaminergic nuclei frequently exhibit both pathological markers (SP and NFT) [<xref ref-type="bibr" rid="R146">146</xref>]. An additional link between the monoaminergic systems and AD pathophysiology is based on genome-wide association studies indicative of relationships between polymorphisms in each monoaminergic system and AD symptomatology (for review [<xref ref-type="bibr" rid="R126">126</xref>]).</p>
<p>Brain imaging, electrophysiological, neurochemical and neuropathological approaches constitute the major tools to investigate brain-behavior relationships in general and hence also the biological underpinnings of NPS. Neuropathological studies of NPS in AD will be the primary focus in subsequent sections dealing with particular NPS, but other relevant approaches (e.g. neuroimaging or electrophysiological approaches) indicative of underlying neuropathological alterations will be briefly touched upon.</p>
<sec>
<label>4.1.</label>
<title>Depression</title>
<p>With prevalence clustering around 20-50%, depression is one of the most frequent comorbid psychiatric disorders in AD with negative consequences for patients and caregivers, including faster cognitive decline, poorer quality of life, greater disability in activities of daily living and a higher mortality rate [<xref ref-type="bibr" rid="R147">147</xref>, <xref ref-type="bibr" rid="R148">148</xref>]. Early-onset depression (&lt; age 65 years) and recurrent depression constitute long-term risk factors for the development of dementia, whereas the onset of more recent depressive symptoms may reflect a prodromal phase of dementia [<xref ref-type="bibr" rid="R149">149</xref>], but the neurobiological mechanism underlying this association is not yet fully understood. Several lines of evidence suggest that depression shares complex pathophysiological routes with dementia.</p>
<p>Several cross-sectional studies were indicative of brain changes associated with AD, including reduced temporal lobe [<xref ref-type="bibr" rid="R150">150</xref>], hippocampal, and amygdala volume [<xref ref-type="bibr" rid="R151">151</xref>, <xref ref-type="bibr" rid="R152">152</xref>] in depressed elderly. In line with the observation that depressive symptoms may indeed be a clinical marker of prodromal AD, depressive symptoms were found to be associated with AD-related neuroanatomical changes, particularly in white matter regions causing brain atrophy [<xref ref-type="bibr" rid="R153">153</xref>]. Compared to other common NPS, as for example apathy, depression is indeed considered an early sign of a more aggressive neurodegenerative process or considered to lower brain reserve capacity, allowing for more rapid progression of AD neuropathology [<xref ref-type="bibr" rid="R154">154</xref>]. Nevertheless, this presumed link was not observed in all studies linking depression and conversion to clinical AD. Results of Royall and Palmer [<xref ref-type="bibr" rid="R155">155</xref>] argue against the role of AD-related neuropathology as a mediator of depression’s effect on cognitive decline, although authors could not rule out a significant mediation effect in a subset of cases, perhaps with more severe baseline depressive symptoms.</p>
<p>A) B)</p>
<p>A lifetime history of major depression in AD was particularly linked to increased plaque and tau-related pathological alterations within the hippocampus. Patients with concurrent major depression present at the time of first diagnosis of AD exhibited an even larger number of hippocampal amyloid plaques and NFT [<xref ref-type="bibr" rid="R159">159</xref>]. Default mode network dysfunction has been proposed to be an important factor in the association between depression and AD [<xref ref-type="bibr" rid="R156">156</xref>-<xref ref-type="bibr" rid="R159">159</xref>].</p>
<p>In addition, depression is considered to be significantly more prevalent in dementia with Lewy bodies (DLB) as compared to AD [<xref ref-type="bibr" rid="R160">160</xref>-<xref ref-type="bibr" rid="R163">163</xref>], potentially reflecting a manifestation of LB pathology. Analogously, a higher likelihood of depression has also been observed in the Lewy body variant of AD versus AD patient cohorts [<xref ref-type="bibr" rid="R164">164</xref>], which is apparently associated with the presence of LBs in the amygdala [<xref ref-type="bibr" rid="R165">165</xref>], the limbic brain region most closely associated with depression in the general population [<xref ref-type="bibr" rid="R166">166</xref>], or in cortical areas [<xref ref-type="bibr" rid="R165">165</xref>]. The presence of LBs is accompanied by neuronal cytoskeleton changes, which may influence neuronal connectivity via alterations to the synaptic network [<xref ref-type="bibr" rid="R167">167</xref>, <xref ref-type="bibr" rid="R168">168</xref>].</p>
<p>Also other brain regions affected by AD pathology have been implicated in depression. A disproportionate loss of noradrenergic locus coeruleus neurons for example has been considered to represent an important organic substrate of depression in AD [<xref ref-type="bibr" rid="R169">169</xref>, <xref ref-type="bibr" rid="R170">170</xref>], which was further substantiated by reduced cortical noradrenergic levels in demented patients with major depression [<xref ref-type="bibr" rid="R171">171</xref>, <xref ref-type="bibr" rid="R172">172</xref>]. In addition, an impaired noradrenergic neurotransmission in the cerebellar cortex might also be associated with depression in AD [<xref ref-type="bibr" rid="R173">173</xref>] (Fig. <bold>4</bold>), which is in line with the fact that a wide range of NPS can be observed following cerebellar pathology [<xref ref-type="bibr" rid="R174">174</xref>].</p>
<p>Interestingly, AD-related neuroinflammation might also (at least partially) lie at the basis of certain NPS, including depression. There is for example mounting evidence that the enzyme indoleamine 2,3-dioxygenase (IDO), which metabolizes the serotonin (5HT) precursor tryptophan into kynurenine, is a prominent player in the relation between chronic inflammation and depression [<xref ref-type="bibr" rid="R175">175</xref>, <xref ref-type="bibr" rid="R176">176</xref>]. IDO activity is upregulated by neuroinflammatory processes, leading to kynurenine catabolization and an overproduction of quinolinic acid, the neurotoxic end product of the tryptophan pathway which may contribute to the excitotoxic effects in AD brain. Moreover, decreased tryptophan levels consequently affect 5HT synthesis, which is a neurochemical hallmark in the etiology of depression. Increased IDO activity can therefore play an important link between neuroinflammation and depression in AD [<xref ref-type="bibr" rid="R177">177</xref>]. Recently, a novel TNF-α-induced proinflammatory agent, neutrophil gelatinase-associated lipocalin (NGAL) or lipocalin 2 (Lcn2), has been linked to both AD [<xref ref-type="bibr" rid="R178">178</xref>] and late-life depression [<xref ref-type="bibr" rid="R179">179</xref>]. Interestingly, plasma NGAL levels are significantly increased in elderly depressed patients with cognitive impairments [<xref ref-type="bibr" rid="R180">180</xref>] and in serum of people with DS [<xref ref-type="bibr" rid="R181">181</xref>], which are both known population groups at risk to develop AD. Neuroinflammation may indeed play a role in depression, or perhaps even in NPS in general.</p>
<p>Cerebral blood flow and metabolism appear to be reduced in depressed compared with non-depressed AD patients in (pre)frontal, temporal and parietal areas [<xref ref-type="bibr" rid="R182">182</xref>-<xref ref-type="bibr" rid="R187">187</xref>]. Depression in AD has also been associated with a significantly larger volume of right parietal white matter hyperintensities [<xref ref-type="bibr" rid="R188">188</xref>].</p>
<p>It is well established that abnormalities in serotonergic neurotransmission are central to the pathophysiology of depression in younger adults, but few studies have examined serotonergic pathological changes in elderly patients and especially in elderly patients in which depression occurs in dementia. One study found no evidence for loss of serotonergic neurons or the presence of neuritic pathology in the dorsal raphe nuclei in older people with depression, with or without comorbid AD [<xref ref-type="bibr" rid="R189">189</xref>], whereas significantly lower cortical 5-HT reuptake sites, as well as hippocampal 5-HT1A receptors and serotonergic compounds were measured in depressed AD patients [<xref ref-type="bibr" rid="R172">172</xref>, <xref ref-type="bibr" rid="R190">190</xref>-<xref ref-type="bibr" rid="R192">192</xref>].</p>
<p>Predictors of depression-related behavior (immobility in a forced swim test and tail suspension test) in mouse models of AD presumably also involve monoaminergic neurotransmitter alterations. The 3×Tg-AD model displays lower basal extracellular output of monoamines in the frontal cortex and ventral hippocampus, accompanied by obvious local Aβ and tau pathology [<xref ref-type="bibr" rid="R193">193</xref>].</p>
</sec>
<sec>
<label>4.2.</label>
<title>Apathy</title>
<p>With reported prevalence rates up to almost 80%, apathy is the most common and persistent NPS in AD [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R194">194</xref>]. It is defined as diminished motivation for at least 4 weeks, accompanied by two of the following symptoms: reduced goal-directed behavior, reduced goal-directed cognitive activity, and reduced emotions [<xref ref-type="bibr" rid="R9">9</xref>]. Several studies have indicated an overlap between apathy and executive dysfunction [<xref ref-type="bibr" rid="R195">195</xref>, <xref ref-type="bibr" rid="R196">196</xref>], both presumably related to dysfunction of thalamic-prefrontal-subcortical circuitry. Since the basal ganglia and their connections with prefrontal cortex are essential to decision-making, fronto-striatal circuit dysfunction may be responsible for the emergence of apathetic behavior in a wide range of neurological disorders [<xref ref-type="bibr" rid="R197">197</xref>].</p>
<p>Apathy is rather difficult to isolate from depression given the frequent comorbidities and a considerable overlap in key symptoms [<xref ref-type="bibr" rid="R194">194</xref>]. Nevertheless, apathy can occur without depression in AD and when depression and apathy co-occur in AD patients, both NPS have been shown to be clinically and anatomically independent [<xref ref-type="bibr" rid="R198">198</xref>, <xref ref-type="bibr" rid="R199">199</xref>]. Response to treatment is also different: antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), seem to have no therapeutic benefit in apathetic patients or can even increase the apathy severity [<xref ref-type="bibr" rid="R200">200</xref>], which may be indicative of differential underlying neurobiological and neurochemical substrates.</p>
<p>Evidence from MCI patients and pre-dementia depressive syndromes has led to the hypothesis that in early AD, apathy may be the result of dysfunctional affective-emotional processing [<xref ref-type="bibr" rid="R201">201</xref>], which takes place in ventromedial prefrontal cortex, and its connections with amygdala and nucleus accumbens. Correspondingly, neuropathological progression in AD targets ventromedial parts of frontal cortex in an early stage [<xref ref-type="bibr" rid="R202">202</xref>-<xref ref-type="bibr" rid="R204">204</xref>]. Apathetic patients have been shown to display significantly greater NFT burden and cortical thinning in left caudal anterior cingulate cortex and left lateral orbitofrontal cortex, as well as left superior and ventrolateral frontal regions, than AD patients lacking apathy symptoms [<xref ref-type="bibr" rid="R205">205</xref>-<xref ref-type="bibr" rid="R207">207</xref>].</p>
<p>Involvement of the anterior cingulate and related frontosubcortical structures, indicative of default mode network dysfunction, in patients with apathy has also been confirmed in various imaging studies [<xref ref-type="bibr" rid="R188">188</xref>, <xref ref-type="bibr" rid="R208">208</xref>-<xref ref-type="bibr" rid="R210">210</xref>].</p>
<p>Besides imaging studies, also several postmortem studies support the hypothesis that dopaminergic circuits linking the basal ganglia with the anterior cingulate and frontal cortices, default mode network structures, normally involved in motivation and reward, may be dysfunctional in people with AD and apathy [<xref ref-type="bibr" rid="R211">211</xref>, <xref ref-type="bibr" rid="R212">212</xref>]. For example, decreased dopamine levels have been reported in the mesolimbic and mesocortical pathway [<xref ref-type="bibr" rid="R213">213</xref>-<xref ref-type="bibr" rid="R215">215</xref>], as well as changes in dopamine receptor density and distribution in apathy-related brain regions [<xref ref-type="bibr" rid="R216">216</xref>-<xref ref-type="bibr" rid="R218">218</xref>].</p>
<p>Pharmacological interventions have also indicated that cholinergic mechanisms may underlie the development of apathy. Improvements in apathy have been noted following cholinesterase inhibitor treatment which has been associated with activation of the ventral striatum [<xref ref-type="bibr" rid="R219">219</xref>, <xref ref-type="bibr" rid="R220">220</xref>].</p>
</sec>
<sec>
<label>4.3.</label>
<title>Agitation and Aggression</title>
<p>The prevalence of agitation and aggression has been reported to range from 48% to 80% in AD patients with persisting symptoms over months and occurring across all AD stages [<xref ref-type="bibr" rid="R221">221</xref>, <xref ref-type="bibr" rid="R222">222</xref>]. Especially physical aggression is a common cause for institutionalization and an important factor in overmedication and the use of physical restraint [<xref ref-type="bibr" rid="R223">223</xref>].</p>
<p>Agitation and aggression in AD have been associated with brain changes in frontal and limbic regions including amygdala, cingulate cortex, and insula. Increased burden of NFT in the orbitofrontal cortex has been linked to agitation and aberrant motor behavior, latter defined as fidgeting, wandering, pacing or rummaging [<xref ref-type="bibr" rid="R205">205</xref>], while aggressive behaviors have been associated with neuronal loss in the rostral noradrenergic locus coeruleus [<xref ref-type="bibr" rid="R224">224</xref>]. Also increased hippocampal NFT load was associated with increased severity of aggressive behaviors and presence of chronic aggression [<xref ref-type="bibr" rid="R225">225</xref>]. Aggressive AD subjects were also shown to display significant hypoperfusion in the left anterior [<xref ref-type="bibr" rid="R226">226</xref>] and right medial temporal cortex [<xref ref-type="bibr" rid="R227">227</xref>]. Greater AD pathology-related amygdala atrophy was also associated with more prominent aberrant motor behavior [<xref ref-type="bibr" rid="R228">228</xref>]. Both agitation and aggression in MCI and AD have been associated with neurodegeneration affecting the anterior salience network, in particular greater atrophy of frontolimbic regions, right posterior cingulate, and left hippocampus, that may reduce capacity to process and regulate behaviors properly [<xref ref-type="bibr" rid="R229">229</xref>].</p>
<p>Cholinergic deficits appear more severe in AD patients displaying agitation or aggression [<xref ref-type="bibr" rid="R230">230</xref>]. In particular, loss of choline acetyltransferase and acetylcholinesterase enzyme activity has been reported in association with this particular NPS item [<xref ref-type="bibr" rid="R219">219</xref>, <xref ref-type="bibr" rid="R230">230</xref>, <xref ref-type="bibr" rid="R231">231</xref>]. Additional evidence comes from the robust clinical improvement of aggression or agitation observed in AD patients receiving cholinesterase inhibitors [<xref ref-type="bibr" rid="R219">219</xref>, <xref ref-type="bibr" rid="R232">232</xref>, <xref ref-type="bibr" rid="R233">233</xref>]. Several neurochemical studies have also linked serotonergic alterations with aggression. Specifically, reduced levels of 5HT and its metabolites were measured in the frontal lobes of aggressive AD patients [<xref ref-type="bibr" rid="R234">234</xref>], in addition to preserved or up-regulated serotonin re-uptake (5-HTT) sites in hippocampus [<xref ref-type="bibr" rid="R192">192</xref>], and an inverse correlation between hippocampal 5-hydroxyindoleacetic acid (5-HIAA; main metabolite of 5-HT) levels and agitation scores [<xref ref-type="bibr" rid="R173">173</xref>]. In addition, the prolactin response to d,l-fenfluramine as an index of central serotonergic function positively correlated to agitation and aggression scores in probable AD patients with severe cognitive impairment and behavioral disturbance, moreover, having interactions with gender and cognitive impairment [<xref ref-type="bibr" rid="R234">234</xref>]. Serotonin transporter (5-HTT) gene-related polymorphisms have been studied with regard to aggression and agitation in AD [<xref ref-type="bibr" rid="R235">235</xref>-<xref ref-type="bibr" rid="R237">237</xref>]. One study reported significant associations between the presence of 5-HTT variable number of tandem repeats sequence allele 10 and NPS or aggressiveness, but failed to show a link with the 5-HTT-linked polymorphic region (5-HTTPR), whereas another study indicated the 5-HTTPR polymorphism to confer risk for a combined psychotic and aggressive AD phenotype.</p>
<p>On the other hand, dopaminergic alterations may also lie at the basis of aggression/agitation in AD; an increased cerebellar dopaminergic turnover was linked to physically agitated behavior [<xref ref-type="bibr" rid="R173">173</xref>] (Fig. <bold>4</bold>). A preservation of cerebellar TH-positive fibers in physically agitated AD subjects, might correspond to preserved (or even upregulated) dopaminergic neuronal endings or fiber sprouting [<xref ref-type="bibr" rid="R238">238</xref>]. In addition, the fact that dopaminergic turnover correlated with frontal lobe symptoms [<xref ref-type="bibr" rid="R173">173</xref>], is potentially indicative of a disrupted cerebello-thalamic-cortical circuit since the cerebellum might modulate aggressive/agitated behavior in AD by influencing prefrontal circuits [<xref ref-type="bibr" rid="R238">238</xref>].</p>
</sec>
<sec>
<label>4.4.</label>
<title>Anxiety and Phobias</title>
<p>Anxieties and phobias in AD have been classically divided into four categories: (1) anxiety regarding upcoming events, for which the term ‘Godot syndrome’ was introduced, (2) other anxieties, e.g. regarding money, (3) fear of being left alone, and (4) other phobias, such as fear of bathing [<xref ref-type="bibr" rid="R3">3</xref>]. Furthermore, physical signs of anxiety are restlessness, pacing and stereotyped behavior. Alternative postulated signs of anxiety include sudden feelings of panic and worrying thoughts [<xref ref-type="bibr" rid="R239">239</xref>]. Results from the Cache County study indicated that 7.9% of patients with AD suffered from anxiety [<xref ref-type="bibr" rid="R240">240</xref>], whereas a Belgian study reported that 29.8% of AD patients were affected by anxieties and/or phobias. This difference might be due to distinct assessment scales and study populations [<xref ref-type="bibr" rid="R241">241</xref>].</p>
<p>There are few studies on structural or metabolic correlates of anxiety in AD. A relatively preserved amygdala volume has been associated with the development of anxiety and irritability in AD, which is in agreement with the relationship between the amygdala and anxiety-related behaviors in non-AD subjects with primary anxiety disorders. In the setting of a reduced ability to interpret the environment and regulate emotional responses, AD patients with relatively preserved amygdala function may exhibit heightened and possibly less differentiated emotional responses that seem inappropriate to caregivers, such as anxiety and irritability [<xref ref-type="bibr" rid="R228">228</xref>]. Anxiety scores correlated with lower metabolism in bilateral entorhinal cortex, anterior parahippocampal gyrus, and left superior temporal gyrus and insula [<xref ref-type="bibr" rid="R242">242</xref>].</p>
<p>Structural, morphological, and cellular alterations in the hippocampus, including among other, a reduced number of pyramidal and granular neurons, a decrease in presynaptic synaptophysin density, and decreased astrocyte complexity, in the absence of Aβ plaques, were associated with cognitive impairment, but also with elevated anxiety scores in the transgenic PDAPP-J20 mouse model of AD [<xref ref-type="bibr" rid="R243">243</xref>].</p>
</sec>
<sec>
<label>4.5.</label>
<title>Psychosis</title>
<p>Psychosis is a common (prevalence 30-50%) and difficult to treat symptom in AD causing diminished quality of life and caregiver distress. Symptoms of AD psychosis are delusions, hallucinations and misidentifications. Criteria for psychosis of AD were proposed by Jeste <italic>et al.</italic> and include: characteristic delusions or hallucinations in the presence of possible or probable AD; onset of the psychotic signs after onset of other dementia symptoms; psychotic symptoms present intermittently for at least 1 month; symptoms severe enough to cause disruption of patients’ or others’ functioning; symptoms not occurring only during a delirium; and symptoms not better accounted for by another psychotic disorder, medical condition or drug [<xref ref-type="bibr" rid="R244">244</xref>]. Although some level of pathology is necessary to give rise to psychoses, patients need to be moderately intellectually preserved in order to elaborate the context of their delusions [<xref ref-type="bibr" rid="R245">245</xref>].</p>
<p>As for depression, psychosis, and particularly visual hallucinations and delusions, seem to have different pathological substrates in DLB versus AD. In AD patients a significant positive association between the presence of neocortical NFT and the occurrence of psychotic symptoms, defined as either visual hallucinations or delusions, was described [<xref ref-type="bibr" rid="R246">246</xref>], while an inverse association between visual hallucinations and NFT staging was observed in DLB [<xref ref-type="bibr" rid="R247">247</xref>]. Interestingly, in patients with presumed Lewy body variant of AD (Braak staging V-VI; Montine B score=3), the frequency of persistent visual hallucinations was more similar to the AD compared to the DLB group (Braak staging 0-VI) [<xref ref-type="bibr" rid="R247">247</xref>], analogously to other studies linking the presence of cortical LB to visual hallucinations and delusions in AD [<xref ref-type="bibr" rid="R248">248</xref>].</p>
<p>Visual hallucinations in AD have been linked to lesions in and atrophy of occipital cortex (visual cortex and association areas) compared to AD patients without visual hallucinations [<xref ref-type="bibr" rid="R249">249</xref>, <xref ref-type="bibr" rid="R250">250</xref>], while delusions have been linked to atrophy in frontal, temporal and limbic regions, including also hippocampus [<xref ref-type="bibr" rid="R206">206</xref>, <xref ref-type="bibr" rid="R251">251</xref>]. Delusional misidentification symptoms in particular have been linked to right frontal lobe atrophy, a reduced number of CA1 pyramidal cells [<xref ref-type="bibr" rid="R245">245</xref>, <xref ref-type="bibr" rid="R252">252</xref>], as well as white matter changes in the bilateral frontal or parieto-occipital region and left basal ganglia [<xref ref-type="bibr" rid="R253">253</xref>], while delusions and hallucinations were observed in AD patients with less cell loss in the parahippocampal gyrus and the dorsal raphe nucleus [<xref ref-type="bibr" rid="R252">252</xref>]. Zubenko <italic>et al</italic>. studied neuropathological and neurochemical correlates of psychosis in AD [<xref ref-type="bibr" rid="R254">254</xref>]. Psychosis (defined as the presence of delusions or hallucinations) was associated with significantly increased densities of SP and NFT in the prosubiculum and middle frontal cortex, respectively, with trends toward increased densities of these lesions in the superior temporal and the entorhinal cortex. Noradrenergic, dopaminergic and serotonergic compounds were measured in the same four cortical regions, as well as in the substantia nigra, thalamus, amygdala, and caudate nucleus. Psychosis was also associated with the relative preservation of norepinephrine in the substantia nigra, with trends in this direction for the majority of the remaining brain regions examined, and a significant reduction of 5HT in the prosubiculum that was accompanied by trends toward reduced levels of serotonin and 5HIAA in the remaining regions [<xref ref-type="bibr" rid="R254">254</xref>]. Disruption of a cohesive noradrenergic locus coeruleus-thalamus linked system, due to advanced locus coeruleus neurodegeneration, has been proposed to potentially lead to psychotic-like behavior in AD [<xref ref-type="bibr" rid="R173">173</xref>], which was, at least partially, substantiated by the observation that thalamic MHPG (<italic>i.e.</italic> 3-methoxy-4-hydroxyphenylglycol, a major noradrenergic metabolite) levels inversely correlated with hallucinations in AD [<xref ref-type="bibr" rid="R173">173</xref>].</p>
<p>Also cholinergic alterations have been linked to psychosis; An increase in M2 muscarinic cholinergic receptors was noted in frontal and temporal cortices of AD patients with psychotic symptoms [<xref ref-type="bibr" rid="R255">255</xref>]. Moreover, treatment with cholinesterase inhibitors also reduced psychotic symptoms in addition to their documented benefits on cognition and global function [<xref ref-type="bibr" rid="R232">232</xref>, <xref ref-type="bibr" rid="R233">233</xref>, <xref ref-type="bibr" rid="R256">256</xref>].</p>
<p>Recently, a decreased dopaminergic neurotransmission and increased dopaminergic catabolism, specifically in the amygdala, was suggested to function as a monoaminergic substrate of psychosis in AD, whereas a generally increased dopaminergic neurotransmitter activity in the prefrontal, temporal and mesolimbic cortices, as well as locus coeruleus and hippocampus, could closely relate to psychosis in DLB. The complexity of an altered coupling between serotonergic and dopaminergic pathways might, additionally, also account differently for the presence of psychosis in DLB compared to that in AD [<xref ref-type="bibr" rid="R257">257</xref>].</p>
<p>Overall, patients with AD who manifest psychosis may have disproportionate dysfunction of frontal lobes and related subcortical and parietal structures [<xref ref-type="bibr" rid="R258">258</xref>]. Moreover, stronger right hemispheric dysfunction in frontal and limbic regions [<xref ref-type="bibr" rid="R259">259</xref>], as well as in the temporal horns [<xref ref-type="bibr" rid="R260">260</xref>] has been associated with the presence of psychosis in AD. Delusional misidentification symptoms have been linked to hypometabolism in paralimbic (orbitofrontal and cingulate areas bilaterally) and left medial temporal areas, and significant bilateral normalized hypermetabolism in sensory association cortices (superior temporal and inferior parietal) without right left asymmetry [<xref ref-type="bibr" rid="R261">261</xref>]. Pronounced brain dysfunction associated with psychosis was also substantiated by electroencephalogram (EEG) abnormalities [<xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R263">263</xref>], with spectral analysis indicating increased delta [<xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R263">263</xref>], and theta [<xref ref-type="bibr" rid="R262">262</xref>] activity, in addition to decreased alpha power [<xref ref-type="bibr" rid="R263">263</xref>].</p>
</sec>
<sec>
<label>4.6.</label>
<title>Sleep and Circadian Rhythm Disturbances</title>
<p>Age-related circadian alterations, with decreased amplitude of the rhythm as well as alterations in circadian phase [<xref ref-type="bibr" rid="R264">264</xref>], are further exacerbated in AD, making sleep disorders common behavioral disturbances in AD, with 25% to 50% of patients experiencing major sleep problems and almost 75% sleeping for extended periods during the day [<xref ref-type="bibr" rid="R265">265</xref>]. Increasing evidence suggests that alterations in circadian rhythms can have profound consequences on emotional behavior and mental health. Disrupted circadian rhythms are also linked to the development of other NPS, such as agitation and restlessness, verbal outbursts, wandering, physical threats, and aggression, often referred to under the umbrella term “sundowning” since they mainly occur during late afternoon and evening [<xref ref-type="bibr" rid="R266">266</xref>].</p>
<p>The hypothalamic suprachiasmatic nucleus (SCN) is considered to be the endogenous clock of the brain. Circadian rhythms not only govern sleep-wake cycles but also rhythms in cognitive processes including subjective alertness, mathematical ability, and memory [<xref ref-type="bibr" rid="R267">267</xref>]. The SCN displays a senescence-related decrease in volume, which is especially pronounced in AD [<xref ref-type="bibr" rid="R268">268</xref>]. Degenerative changes in the SCN include neuronal loss and NFT, whereas amyloid plaques are only seldom noted in the SCN [<xref ref-type="bibr" rid="R269">269</xref>]. Nevertheless, indices for amyloid deposition (<italic>i.e.</italic>, cerebrospinal fluid Aβ<sub>1-42</sub> levels) in the preclinical stage of AD appeared to be associated with worse sleep quality [<xref ref-type="bibr" rid="R270">270</xref>]. Recently, cortical Aβ pathology was associated with impaired generation of non-rapid eye movement slow wave oscillations that, in turn, predicted disturbed long-term hippocampus-dependent memory consolidation [<xref ref-type="bibr" rid="R271">271</xref>].</p>
<p>Several lines of evidence implicate alterations in melatonin levels in AD as a possible neurochemical mediator of circadian changes. Interestingly, in addition to melatonin’s ability to regulate circadian rhythms [<xref ref-type="bibr" rid="R272">272</xref>], melatonin has also been demonstrated to be a potent antioxidant and neuroprotector against oxidative stress and Aβ-based toxicity [<xref ref-type="bibr" rid="R273">273</xref>]. CSF melatonin levels decrease with the progression of AD neuropathology, already in cognitively intact subjects with the earliest AD neuropathology (Braak stages I-II, <italic>i.e.</italic> preclinical AD) [<xref ref-type="bibr" rid="R274">274</xref>]. Decreased night-time melatonin in the pineal gland of AD brain is accompanied by neurotransmitter abnormalities relevant to melatonin regulation [<xref ref-type="bibr" rid="R275">275</xref>]. More specifically, Braak stage-dependent dysregulation of pineal β1-adrenergic receptor mRNA and the increased monoamine oxidase A activity, as reflected by the 5-HIAA:5-HT ratio, and mRNA levels were held responsible for the disappearance of the melatonin diurnal rhythm and the decrease of nocturnal melatonin synthesis in preclinical AD subjects and AD patients [<xref ref-type="bibr" rid="R275">275</xref>].</p>
<p>Another brain area that undergoes neurodegeneration in AD and might be important for circadian rhythm disturbance is the cholinergic basal forebrain. Cells of the nucleus basalis project to the SCN, and cholinergic agents act in the SCN to modulate circadian rhythms [<xref ref-type="bibr" rid="R265">265</xref>]. An AD mouse model study has reported alterations in non–rapid eye movement sleep that could be due to alterations in cholinergic transmission [<xref ref-type="bibr" rid="R276">276</xref>], but clinical studies concerning the role of cholinergic depletion in circadian disturbance in AD are still lacking.</p>
<p>Sleep disturbance has been associated with vascular pathology in studies examining the incidence and severity of NPS [<xref ref-type="bibr" rid="R277">277</xref>-<xref ref-type="bibr" rid="R279">279</xref>]. Accordingly, increased white matter hyperintensities, reflecting vascular pathology of the white matter, which may be of Aβ-related origin, have been association with sleep disturbances in AD [<xref ref-type="bibr" rid="R279">279</xref>].</p>
<p>Of interest is the fact that rapid eye movement sleep behavior disorder, in which acting out of dream behavior is associated with preservation of body tone, is more common in synucleinopathies than in tauopathies, to the extent that some suggest that its presence may be a diagnostic feature [<xref ref-type="bibr" rid="R280">280</xref>].</p>
</sec>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSION</title>
<p>A large body of evidence, of which only a sample set of studies were discussed in this review, clearly indicates that NPS in AD are associated with neurodegeneration affecting specific neural pathways, networks and circuits and that they are based on the interplay of neuropathological and neurochemical factors in the pathogenesis of AD. It is therefore well established that in the vast majority of cases, NPS are fundamental expressions of the underlying neurodegenerative brain disease and not simply reflect the patients’ secondary response to his illness. Nevertheless, further refinement of the nosology of NPS is required since we are only beginning to understand the underlying pathophysiology. In addition, it is important to take into consideration that interpretation and comparison of biological NPS-related studies can be restricted by relatively small sample sizes (e.g. numbers of patients or brain regions included), variations in study design or measurement of included parameters. Neuropathological studies, moreover, include a majority of end-stage patient samples, which may not correctly represent the pathophysiological environment responsible for particular NPS that may already be present in an early stage, or even prior to AD diagnosis. The burdensome nature and prevalent occurrence of NPS, in combination with the fact that effective and safe treatment options are still lacking, provide a strong incentive to continue neuropathological and neurochemical, as well as of course imaging and other relevant approaches to further improve our apprehension of the neurobiology of NPS.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>The work of all included authors was supported by the Research Foundation-Flanders (FWO), Interuniversity Poles of Attraction (IAP Network P7/16) of the Belgian Federal Science Policy Office, Methusalem excellence grant of the Flemish Government, agreement between Institute Born-Bunge and University of Antwerp, the Medical Research Foundation Antwerp, the Thomas Riellaerts research fund, Neurosearch Antwerp, and the Alzheimer Research Center of the University Medical Center Groningen (UMCG). A.D.D. was granted a PhD fellowship of the Research School of Behavioural and Cognitive Neurosciences of the UMCG.</p>
<p>All authors have contributed substantially to the design and writing of the review, as well as inclusion and interpretation of included research.</p>
</ack>
<sec>
<title>CONFLICT OF INTEREST</title>
<p>The authors confirm that this article content has no  conflict of interest.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia.</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2004</year>
<volume>75</volume>
<fpage>61</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">14707310</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geda</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Gitlin</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future.</article-title>
<source/>Alzheimers Dement.
          <year>2013</year>
<volume>9</volume>
<fpage>602</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="pmid">23562430</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reisberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Borenstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salob</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Ferris</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Franssen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Georgotas</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment.</article-title>
<source/>J. Clin. Psychiatry
          <year>1987</year>
<volume>48</volume>
<fpage>9</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Mega</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rosenberg-Thompson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carusi</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Gornbein</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.</article-title>
<source/>Neurology
          <year>1994</year>
<volume>44</volume>
<fpage>2308</fpage>
<lpage>2314</lpage>
<pub-id pub-id-type="pmid">7991117</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mega</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Fiorello</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gornbein</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The spectrum of behavioral changes in Alzheimer’s disease.</article-title>
<source/>Neurology
          <year>1996</year>
<volume>46</volume>
<fpage>130</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">8559361</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.</article-title>
<source/>Neurology
          <year>1997</year>
<volume>48</volume>
<fpage>S10</fpage>
<lpage>S16</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Carrillo</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Khachaturian</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Trzepacz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Amatniek</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric symptoms in Alzheimer’s disease.</article-title>
<source/>Alzheimers Dement.
          <year>2011</year>
<volume>7</volume>
<fpage>532</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="pmid">21889116</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finkel</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Costa e Silva</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sartorius</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment.</article-title>
<source/>Int. Psychogeriatr.
          <year>1996</year>
<volume>8</volume>
<fpage>497</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="pmid">9154615</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Breitner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.</article-title>
<source/>JAMA
          <year>2002</year>
<volume>288</volume>
<fpage>1475</fpage>
<lpage>1483</lpage>
<pub-id pub-id-type="pmid">12243634</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Plassman</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Steffens</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Llewellyn</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Langa</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study.</article-title>
<source/>J. Am. Geriatr. Soc.
          <year>2011</year>
<volume>59</volume>
<fpage>473</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="pmid">21391937</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>González-Salvador</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Arango</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Barba</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>The stress and psychological morbidity of the Alzheimer patient caregiver.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>1999</year>
<volume>14</volume>
<fpage>701</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="pmid">10479740</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuel</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Houck</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Weamer</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Demichele-Sweet</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study.</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2011</year>
<volume>19</volume>
<fpage>160</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="pmid">20808116</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douglas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Letts</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A systematic review of accidental injury from fire, wandering and medication self-administration errors for older adults with and without dementia.</article-title>
<source/>Arch. Gerontol. Geriatr.
          <year>2011</year>
<volume>52</volume>
<fpage>e1</fpage>
<lpage>e10</lpage>
<pub-id pub-id-type="pmid">20334937</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lanctôt</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Sambrook</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lesnikova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of neuropsychiatric symptoms to the cost of dementia care.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2006</year>
<volume>21</volume>
<fpage>972</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="pmid">16955429</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>DSM-V: Diagnostic and Statistical Manual of Mental Disorders.
          <year>2013</year>
<edition>5th ed</edition>
<publisher-loc>Washington, DC</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gauthier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brodaty</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Grossberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Management of behavioral problems in Alzheimer’s disease.</article-title>
<source/>Int. Psychogeriatr.
          <year>2010</year>
<volume>22</volume>
<fpage>346</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="pmid">20096151</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Drug discovery in dementia: the role of rodent models.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2006</year>
<volume>5</volume>
<fpage>956</fpage>
<lpage>970</lpage>
<pub-id pub-id-type="pmid">17080031</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Animal models in the drug discovery pipeline for Alzheimer's disease.</article-title>
<source/>Br. J. Pharmacol.
          <year>2011</year>
<volume>164</volume>
<fpage>1285</fpage>
<lpage>1300</lpage>
<pub-id pub-id-type="pmid">21371009</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lansbury</surname>
<given-names>P.T.</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information.</article-title>
<source/>Biochemistry
          <year>1992</year>
<volume>31</volume>
<fpage>6865</fpage>
<lpage>6870</lpage>
<pub-id pub-id-type="pmid">1637821</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Peers</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Physiological roles for amyloid beta peptides.</article-title>
<source/>J. Physiol.
          <year>2006</year>
<volume>575</volume>
<fpage>5</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">16809372</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parihar</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Brewer</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Amyloid-beta as a modulator of synaptic plasticity.</article-title>
<source/>J. Alzheimers Dis.
          <year>2010</year>
<volume>22</volume>
<fpage>741</fpage>
<lpage>763</lpage>
<pub-id pub-id-type="pmid">20847424</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Lieber</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lansbury</surname>
<given-names>P.T.</given-names>
</name>
</person-group>
<article-title>Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.</article-title>
<source/>Chem. Biol.
          <year>1997</year>
<volume>4</volume>
<fpage>119</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="pmid">9190286</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Barlow</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Chromy</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Freed</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liosatos</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1998</year>
<volume>95</volume>
<fpage>6448</fpage>
<lpage>6453</lpage>
<pub-id pub-id-type="pmid">9600986</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roher</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Lowenson</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wolkow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>R.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.</article-title>
<source/>J. Biol. Chem.
          <year>1993</year>
<volume>268</volume>
<fpage>3072</fpage>
<lpage>3083</lpage>
<pub-id pub-id-type="pmid">8428986</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwatsubo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Odaka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mizusawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nukina</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ihara</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).</article-title>
<source/>Neuron
          <year>1994</year>
<volume>13</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">8043280</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrano-Pozo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frosch</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>B.T.</given-names>
</name>
</person-group>
<article-title>Neuropathological alterations in Alzheimer disease.</article-title>
<source/>Cold Spring Harb. Perspect. Med.
          <year>2011</year>
<volume>1</volume>
<fpage>a006189</fpage>
<pub-id pub-id-type="pmid">22229116</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selkoe</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Alzheimer's disease.</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2011</year>
<volume>3</volume>
<fpage>a004457</fpage>
<pub-id pub-id-type="pmid">21576255</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Urbanc</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Buldyrev</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Christie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gomez-Isla</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Havlin</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aggregation and disaggregation of senile plaques in Alzheimer disease.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>7612</fpage>
<lpage>7616</lpage>
<pub-id pub-id-type="pmid">9207140</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thal</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saido</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Fandrich</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease.</article-title>
<source/>Acta Neuropathol.
          <year>2015</year>
<volume>129</volume>
<fpage>167</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="pmid">25534025</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacor</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Buniel</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Furlow</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Clemente</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease.</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<fpage>796</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">17251419</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goate</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chartier-Harlin</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Mullan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fidani</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.</article-title>
<source/>Nature
          <year>1991</year>
<volume>349</volume>
<fpage>704</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="pmid">1671712</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tandon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mullan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>St George-Hyslop</surname>
<given-names>P.H.</given-names>
</name>
</person-group>
<article-title>Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins.</article-title>
<source/>Curr. Opin. Neurol.
          <year>2000</year>
<volume>13</volume>
<fpage>377</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">10970053</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilatela</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Lopez-Lopez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yeseas-Gomez</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Genetics of Alzheimer's Disease.</article-title>
<source/>Arch. Med. Res.
          <year>2012</year>
<volume>43</volume>
<fpage>622</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="pmid">23142261</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blennow</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>de Leon</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Alzheimer's disease.</article-title>
<source/>Lancet
          <year>2006</year>
<volume>368</volume>
<fpage>387</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="pmid">16876668</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.</article-title>
<source/>Science
          <year>2002</year>
<volume>297</volume>
<fpage>353</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="pmid">12130773</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teipel</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Hampel</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Neuroanatomy of Down syndrome <italic>in vivo</italic>: a model of preclinical Alzheimer's disease.</article-title>
<source/>Behav. Genet.
          <year>2006</year>
<volume>36</volume>
<fpage>405</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">16485178</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zigman</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Lott</surname>
<given-names>I.T.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s Disease in Down Syndrome: Neurobiology and Risk.</article-title>
<source/>Ment. Retard. Dev. Disabil. Res. Rev.
          <year>2007</year>
<volume>13</volume>
<fpage>237</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="pmid">17910085</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zigman</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>Atypical aging in down syndrome.</article-title>
<source/>Dev. Disabil. Res. Rev.
          <year>2013</year>
<volume>18</volume>
<fpage>51</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">23949829</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiseman</surname>
<given-names>F.K.</given-names>
</name>
<name>
<surname>Al-Janabi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karmiloff-Smith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nizetic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tybulewicz</surname>
<given-names>V.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2015</year>
<volume>16</volume>
<issue>9</issue>
<fpage>564</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="pmid">26243569</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feightner</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>G.Y.</given-names>
</name>
<name>
<surname>MacKnight</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sadovnick</surname>
<given-names>A.D.</given-names>
</name>
</person-group>
<article-title>Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease.</article-title>
<source/>CMAJ
          <year>2008</year>
<volume>178</volume>
<fpage>548</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="pmid">18299540</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Bales</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Tenkova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Parsadanian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sartorius</surname>
<given-names>L.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2000</year>
<volume>97</volume>
<fpage>2892</fpage>
<lpage>2897</lpage>
<pub-id pub-id-type="pmid">10694577</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jack</surname>
<given-names>C.R.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Knopman</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Jagust</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Aisen</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>M.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.</article-title>
<source/>Lancet Neurol.
          <year>2010</year>
<volume>9</volume>
<fpage>119</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">20083042</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borchelt</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Thinakaran</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Eckman</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ratovitsky</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio <italic>in vitro</italic> and <italic>in vivo.</italic></article-title>
<source/>Neuron
          <year>1996</year>
<volume>17</volume>
<fpage>1005</fpage>
<lpage>1013</lpage>
<pub-id pub-id-type="pmid">8938131</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eckman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zehr</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Prada</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Perez-tur</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.</article-title>
<source/>Nature
          <year>1996</year>
<volume>383</volume>
<fpage>710</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="pmid">8878479</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lendon</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Froelich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.</article-title>
<source/>Nature
          <year>1998</year>
<volume>393</volume>
<fpage>702</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="pmid">9641683</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Chisholm</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Corral</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.</article-title>
<source/>Science
          <year>2001</year>
<volume>293</volume>
<fpage>1487</fpage>
<lpage>1491</lpage>
<pub-id pub-id-type="pmid">11520987</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliver</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crayton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bradbury</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A four year prospective study of age-related cognitive change in adults with Down's syndrome.</article-title>
<source/>Psychol. Med.
          <year>1998</year>
<volume>28</volume>
<fpage>1365</fpage>
<lpage>1377</lpage>
<pub-id pub-id-type="pmid">9854278</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arriagada</surname>
<given-names>P.V.</given-names>
</name>
<name>
<surname>Growdon</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Hedley-Whyte</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>B.T.</given-names>
</name>
</person-group>
<article-title>Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.</article-title>
<source/>Neurology
          <year>1992</year>
<volume>42</volume>
<fpage>631</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="pmid">1549228</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karran</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mercken</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Strooper</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2011</year>
<volume>10</volume>
<fpage>698</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="pmid">21852788</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisniewski</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>G.Y.</given-names>
</name>
</person-group>
<article-title>ccurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.</article-title>
<source/>Ann. Neurol.
          <year>1985</year>
<volume>17</volume>
<fpage>278</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">3158266</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lott</surname>
<given-names>I.T.</given-names>
</name>
<name>
<surname>Dierssen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cognitive deficits and associated neurological complications in individuals with Down’s syndrome.</article-title>
<source/>Lancet Neurol.
          <year>2010</year>
<volume>9</volume>
<fpage>623</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="pmid">20494326</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jucker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.</article-title>
<source/>Ann. Neurol.
          <year>2011</year>
<volume>70</volume>
<fpage>532</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="pmid">22028219</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Flory</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Damasio</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Van Hoesen</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease.</article-title>
<source/>Cereb. Cortex
          <year>1991</year>
<volume>1</volume>
<fpage>103</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">1822725</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neuropathological stageing of Alzheimer-related changes.</article-title>
<source/>Acta Neuropathol.
          <year>1991</year>
<volume>82</volume>
<fpage>239</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">1759558</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thal</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Rüb</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Orantes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Phases of Aβ deposition in the human brainn and its relevance for the development of AD.</article-title>
<source/>Neurology
          <year>2002</year>
<volume>58</volume>
<fpage>1791</fpage>
<lpage>1800</lpage>
<pub-id pub-id-type="pmid">12084879</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montine</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Phelps</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.</article-title>
<source/>Acta Neuropathol.
          <year>2012</year>
<volume>123</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">22101365</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Quijada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Terry</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies.</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>1988</year>
<volume>47</volume>
<fpage>393</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">2838588</pub-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perl</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Neuropathology of Alzheimer's disease.</article-title>
<source/>Mt Sinai J Med New
          <year>2010</year>
<volume>77</volume>
<fpage>32</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mesulam</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Asuncion</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.</article-title>
<source/>Ann. Neurol.
          <year>1987</year>
<volume>22</volume>
<fpage>223</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">3662453</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alonso Adel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chohan</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>El-Akkad</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tau pathology in Alzheimer disease and other tauopathies.</article-title>
<source/>Biochim. Biophys. Acta
          <year>2005</year>
<volume>1739</volume>
<fpage>198</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">15615638</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Griffing</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bohl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bratzke</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>1999</year>
<volume>249</volume>
<fpage>14</fpage>
<lpage>22</lpage>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mandelkow</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.</article-title>
<source/>Acta Neuropathol.
          <year>1994</year>
<volume>87</volume>
<fpage>554</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="pmid">7522386</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villemagne</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>
<italic>In vivo</italic> tau imaging: obstacles and progress.</article-title>
<source/>Alzheimers Dement.
          <year>2014</year>
<volume>10</volume>
<fpage>S254</fpage>
<lpage>S64</lpage>
<pub-id pub-id-type="pmid">24924676</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villemagne</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Fodero-Tavoletti</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Masters</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Tau imaging: early progress and future directions.</article-title>
<source/>Lancet Neurol.
          <year>2015</year>
<volume>14</volume>
<fpage>114</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">25496902</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soto</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Unfolding the role of protein misfolding in neurodegenerative diseases.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2003</year>
<volume>4</volume>
<fpage>49</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">12511861</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.</article-title>
<source/>Brain Pathol.
          <year>2000</year>
<volume>10</volume>
<fpage>378</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">10885656</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Galasko</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>DeTeresa</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity.</article-title>
<source/>Neurology
          <year>1990</year>
<volume>40</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olichney</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Galasko</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Hofstetter</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease.</article-title>
<source/>Neurology
          <year>1998</year>
<volume>51</volume>
<fpage>351</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="pmid">9710002</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Blurton-Jones</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Examining the mechanisms that link b-amyloid and a-synuclein pathologies.</article-title>
<source/>Alzheimers Res. Ther.
          <year>2012</year>
<volume>4</volume>
<fpage>11</fpage>
<pub-id pub-id-type="pmid">22546279</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resende</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Ferreiro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Simões</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.</article-title>
<source/>Neurochem. Res.
          <year>2013</year>
<volume>38</volume>
<fpage>797</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="pmid">23389658</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Fourteen and counting: unraveling trinucleotide repeat diseases.</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<fpage>909</fpage>
<lpage>916</lpage>
<pub-id pub-id-type="pmid">10767314</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujigasaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Camuzat</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deffond</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stevanin</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia.</article-title>
<source/>Brain
          <year>2001</year>
<volume>124</volume>
<fpage>1939</fpage>
<lpage>1947</lpage>
<pub-id pub-id-type="pmid">11571212</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>van Roon-Mom</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Faull</surname>
<given-names>R.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease.</article-title>
<source/>Brain Res. Mol. Brain Res.
          <year>2004</year>
<volume>125</volume>
<fpage>120</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">15193429</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruijn</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Houseweart</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Ohama</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.</article-title>
<source/>Science
          <year>1998</year>
<volume>281</volume>
<fpage>1851</fpage>
<lpage>1854</lpage>
<pub-id pub-id-type="pmid">9743498</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>H.D.</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Levey</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases.</article-title>
<source/>J. Biol. Chem.
          <year>2005</year>
<volume>280</volume>
<fpage>11648</fpage>
<lpage>11655</lpage>
<pub-id pub-id-type="pmid">15659387</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Ubiquitin pathways in neurodegenerative disease.</article-title>
<source/>Front. Mol. Neurosci.
          <year>2014</year>
<volume>7</volume>
<fpage>63</fpage>
<pub-id pub-id-type="pmid">25071440</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chau</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1987</year>
<volume>84</volume>
<fpage>3033</fpage>
<lpage>3036</lpage>
<pub-id pub-id-type="pmid">3033674</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhya</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Role of the ubiquitin proteasome system in Alzheimer's disease.</article-title>
<source/>BMC Biochem.
          <year>2007</year>
<volume>8</volume>
<fpage>S12</fpage>
<pub-id pub-id-type="pmid">18047736</pub-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riederer</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Leuba</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vernay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>I.M.</given-names>
</name>
</person-group>
<article-title>The role of the ubiquitin proteasome system in Alzheimer's disease.</article-title>
<source/>Exp. Biol. Med. (Maywood)
          <year>2011</year>
<volume>236</volume>
<fpage>268</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">21383047</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sampathu</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Truax</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Micsenyi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>T.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</article-title>
<source/>Science
          <year>2006</year>
<volume>314</volume>
<fpage>130</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">17023659</pub-id>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josephs</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Whitwell</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Stroh</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<fpage>1850</fpage>
<lpage>1857</lpage>
<pub-id pub-id-type="pmid">18401022</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uryu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakashima-Yasuda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>2008</year>
<volume>67</volume>
<fpage>555</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="pmid">18520774</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadokura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lemere</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Takatama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.</article-title>
<source/>Neuropathology
          <year>2009</year>
<volume>29</volume>
<fpage>566</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="pmid">19422539</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Khandelwal</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Stanczyk</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Rebeck</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Moussa</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>β-amyloid triggers ALS-associated TDP-43 pathology in AD models.</article-title>
<source/>Brain Res.
          <year>2011</year>
<volume>1386</volume>
<fpage>191</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">21376022</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Barger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barnum</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bradt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammation and Alzheimer's disease.</article-title>
<source/>Neurobiol. Aging
          <year>2000</year>
<volume>21</volume>
<fpage>383</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="pmid">10858586</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hensley</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation.</article-title>
<source/>J. Alzheimers Dis.
          <year>2010</year>
<volume>21</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">20182045</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>El Khoury</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Brosseron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>D.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroinflammation in Alzheimer's disease.</article-title>
<source/>Lancet Neurol.
          <year>2015</year>
<volume>14</volume>
<fpage>388</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">25792098</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kettenmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hanisch</surname>
<given-names>U.K.</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Verkhratsky</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Physiology of microglia.</article-title>
<source/>Physiol. Rev.
          <year>2011</year>
<volume>91</volume>
<fpage>461</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="pmid">21527731</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reed-Geaghan</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Hise</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>CD14 and Toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation.</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>11982</fpage>
<lpage>11992</lpage>
<pub-id pub-id-type="pmid">19776284</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ostaszewski</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yanagisawa</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Soluble Aβ oligomers are rapidly sequestered from brain ISF <italic>in vivo</italic> and bind GM1 ganglioside on cellular membranes.</article-title>
<source/>Neuron
          <year>2014</year>
<volume>82</volume>
<fpage>308</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="pmid">24685176</pub-id>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beauquis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vinuesa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pomilio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pavía</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Galván</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Saravia</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer's disease.</article-title>
<source/>Hippocampus
          <year>2014</year>
<volume>24</volume>
<fpage>257</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">24132937</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mrak</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>W.S.</given-names>
</name>
</person-group>
<article-title>Glial cytokines in Alzheimer's disease: review and pathogenic implications.</article-title>
<source/>Hum. Pathol.
          <year>1995</year>
<volume>26</volume>
<fpage>816</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="pmid">7635444</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kawamata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tooyama</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>P.L.</given-names>
</name>
</person-group>
<article-title>Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders.</article-title>
<source/>Acta Neuropathol.
          <year>1993</year>
<volume>85</volume>
<fpage>628</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="pmid">8337942</pub-id>
</element-citation>
</ref>
<ref id="R94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savarin-Vuaillat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ransohoff</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?</article-title>
<source/>Neurotherapeutics
          <year>2007</year>
<volume>4</volume>
<fpage>590</fpage>
<lpage>601</lpage>
<pub-id pub-id-type="pmid">17920540</pub-id>
</element-citation>
</ref>
<ref id="R95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohn</surname>
<given-names>T.T.</given-names>
</name>
</person-group>
<article-title>The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities.</article-title>
<source/>Apoptosis
          <year>2010</year>
<volume>15</volume>
<fpage>1403</fpage>
<lpage>1409</lpage>
<pub-id pub-id-type="pmid">20127416</pub-id>
</element-citation>
</ref>
<ref id="R96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montine</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Sidell</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Markesbery</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Marnett</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>L.J.</given-names>
<suffix>II</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Elevated CSF prostaglandin E2 levels in patients with probable AD.</article-title>
<source/>Neurology
          <year>1999</year>
<volume>53</volume>
<fpage>1495</fpage>
<lpage>1498</lpage>
<pub-id pub-id-type="pmid">10534257</pub-id>
</element-citation>
</ref>
<ref id="R97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strohmeyer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain.</article-title>
<source/>J. Neuroimmunol.
          <year>2002</year>
<volume>131</volume>
<fpage>135</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">12458045</pub-id>
</element-citation>
</ref>
<ref id="R98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vodovotz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lucia</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Flanders</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Chesler</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Q.W.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.</article-title>
<source/>J. Exp. Med.
          <year>1996</year>
<volume>184</volume>
<fpage>1425</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="pmid">8879214</pub-id>
</element-citation>
</ref>
<ref id="R99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iadecola</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Neurovascular regulation in the normal brain and in Alzheimer's disease.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2004</year>
<volume>5</volume>
<fpage>347</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">15100718</pub-id>
</element-citation>
</ref>
<ref id="R100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sofroniew</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>H.V.</given-names>
</name>
</person-group>
<article-title>Astrocytes: biology and pathology.</article-title>
<source/>Acta Neuropathol.
          <year>2010</year>
<volume>119</volume>
<fpage>7</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">20012068</pub-id>
</element-citation>
</ref>
<ref id="R101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najjar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pearlman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Alper</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Najjar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and psychiatric illness.</article-title>
<source/>J. Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>43</fpage>
<pub-id pub-id-type="pmid">23547920</pub-id>
</element-citation>
</ref>
<ref id="R102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itagaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Relationship of microglia and astrocytes to amyloid deposits of Alzheimer’s disease.</article-title>
<source/>J. Neuroimmunol.
          <year>1989</year>
<volume>24</volume>
<fpage>173</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="pmid">2808689</pub-id>
</element-citation>
</ref>
<ref id="R103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pike</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Early association of reactive astrocytes with senile plaques in Alzheimer’s disease.</article-title>
<source/>Exp. Neurol.
          <year>1995</year>
<volume>132</volume>
<fpage>172</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">7789457</pub-id>
</element-citation>
</ref>
<ref id="R104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrano-Pozo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mielke</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Gómez-Isla</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Betensky</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Growdon</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Frosch</surname>
<given-names>M.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease.</article-title>
<source/>Am. J. Pathol.
          <year>2011</year>
<volume>179</volume>
<fpage>1373</fpage>
<lpage>1384</lpage>
<pub-id pub-id-type="pmid">21777559</pub-id>
</element-citation>
</ref>
<ref id="R105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozyczko-Coyne</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O'Kane</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.L.</given-names>
</name>
<name>
<surname>Dobrzanski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vaught</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis.</article-title>
<source/>J. Neurochem.
          <year>2001</year>
<volume>77</volume>
<fpage>849</fpage>
<lpage>863</lpage>
<pub-id pub-id-type="pmid">11331414</pub-id>
</element-citation>
</ref>
<ref id="R106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morishima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gotoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zieg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand.</article-title>
<source/>J. Neurosci.
          <year>2001</year>
<volume>21</volume>
<fpage>7551</fpage>
<lpage>7560</lpage>
<pub-id pub-id-type="pmid">11567045</pub-id>
</element-citation>
</ref>
<ref id="R107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canevari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Duchen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress.</article-title>
<source/>Neurochem. Res.
          <year>2004</year>
<volume>29</volume>
<fpage>637</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="pmid">15038611</pub-id>
</element-citation>
</ref>
<ref id="R108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donev</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kolev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Millet</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Neuronal death in Alzheimer’s disease and therapeutic opportunities.</article-title>
<source/>J. Cell. Mol. Med.
          <year>2009</year>
<volume>13</volume>
<fpage>4329</fpage>
<lpage>4348</lpage>
<pub-id pub-id-type="pmid">19725918</pub-id>
</element-citation>
</ref>
<ref id="R109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morishima-Kawashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oshima</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugihara</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain.</article-title>
<source/>Am. J. Pathol.
          <year>2000</year>
<volume>157</volume>
<fpage>2093</fpage>
<lpage>2099</lpage>
<pub-id pub-id-type="pmid">11106581</pub-id>
</element-citation>
</ref>
<ref id="R110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lue</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Roher</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Brachova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.</article-title>
<source/>Am. J. Pathol.
          <year>1999</year>
<volume>155</volume>
<fpage>853</fpage>
<lpage>862</lpage>
<pub-id pub-id-type="pmid">10487842</pub-id>
</element-citation>
</ref>
<ref id="R111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>G.Q.</given-names>
</name>
<name>
<surname>Mallory</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rockenstein</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Tatsuno</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.</article-title>
<source/>J. Neurosci.
          <year>2000</year>
<volume>20</volume>
<fpage>4050</fpage>
<lpage>4058</lpage>
<pub-id pub-id-type="pmid">10818140</pub-id>
</element-citation>
</ref>
<ref id="R112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeKosky</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Scheff</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity.</article-title>
<source/>Ann. Neurol.
          <year>1990</year>
<volume>27</volume>
<fpage>457</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="pmid">2360787</pub-id>
</element-citation>
</ref>
<ref id="R113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Quantative assessment of cortical synaptic density in Alzheimer’s disease.</article-title>
<source/>Neurobiol. Aging
          <year>1990</year>
<volume>11</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">2325814</pub-id>
</element-citation>
</ref>
<ref id="R114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Terry</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The role of synaptic pathology in the mechanisms of dementia in Alzheimer’s disease.</article-title>
<source/>Clin. Neurosci.
          <year>1994</year>
<volume>1</volume>
<fpage>192</fpage>
<lpage>198</lpage>
</element-citation>
</ref>
<ref id="R115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonatas</surname>
<given-names>N.K.</given-names>
</name>
</person-group>
<article-title>Neocortical synapses in a presenile dementia.</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>1967</year>
<volume>26</volume>
<fpage>150</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">6022142</pub-id>
</element-citation>
</ref>
<ref id="R116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baloyannis</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Dendritic pathology in Alzheimer's disease.</article-title>
<source/>J. Neurol. Sci.
          <year>2009</year>
<volume>283</volume>
<fpage>153</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">19296966</pub-id>
</element-citation>
</ref>
<ref id="R117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nissanov</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mitchel</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Bennet</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Trojanowski</surname>
<given-names>J.O.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Subiculum dendritic arborization in Alzheimer's disease correlates with neurofibrillary tangle density.</article-title>
<source/>Am. J. Pathol.
          <year>2006</year>
<volume>163</volume>
<fpage>1615</fpage>
<lpage>1631</lpage>
</element-citation>
</ref>
<ref id="R118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baloyannis</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mauroudis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Psaroulis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Manolides</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Manolides</surname>
<given-names>L.S.</given-names>
</name>
</person-group>
<article-title>Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological and morphometric estimation by Golgi technique and electron microscopy.</article-title>
<source/>Acta Otolaryngol.
          <year>1953</year>
<volume>127</volume>
<fpage>351</fpage>
<lpage>354</lpage>
</element-citation>
</ref>
<ref id="R119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paula-Barbosa</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Guimaraes</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Dendritic degeneration and regrowth in the cerebral cortex of patients with Alzheimer's disease.</article-title>
<source/>J. Neurol. Sci.
          <year>1980</year>
<volume>45</volume>
<fpage>129</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">7359162</pub-id>
</element-citation>
</ref>
<ref id="R120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baloyannis</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Manolides</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Manolides</surname>
<given-names>L.S.</given-names>
</name>
</person-group>
<article-title>Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological estimation in Golgi technique and electron microscopy.</article-title>
<source/>Acta Otolaryngol.
          <year>2011</year>
<volume>131</volume>
<fpage>610</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="pmid">21198341</pub-id>
</element-citation>
</ref>
<ref id="R121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mavroudis</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Fotiou</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Manani</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Njaou</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Frangou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>V.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dendritic pathology and spinal loss in the visual cortex in Alzheimer's disease: a Golgi study in pathology.</article-title>
<source/>Int. J. Neurosci.
          <year>2011</year>
<volume>121</volume>
<fpage>347</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="pmid">21545306</pub-id>
</element-citation>
</ref>
<ref id="R122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kummer</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Truncated and modified amyloid-beta species.</article-title>
<source/>Alzheimers Res. Ther.
          <year>2014</year>
<volume>6</volume>
<fpage>28</fpage>
<pub-id pub-id-type="pmid">25031638</pub-id>
</element-citation>
</ref>
<ref id="R123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Crutcher</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>DeLong</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions.</article-title>
<source/>Prog. Brain Res.
          <year>1990</year>
<volume>85</volume>
<fpage>119</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">2094891</pub-id>
</element-citation>
</ref>
<ref id="R124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Frontal-subcortical circuits and human behavior.</article-title>
<source/>Arch. Neurol.
          <year>1993</year>
<volume>50</volume>
<fpage>873</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="pmid">8352676</pub-id>
</element-citation>
</ref>
<ref id="R125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mesulam</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>From sensation to cognition.</article-title>
<source/>Brain
          <year>1998</year>
<volume>121</volume>
<fpage>1013</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="pmid">9648540</pub-id>
</element-citation>
</ref>
<ref id="R126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trillo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Moghadam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2013</year>
<volume>37</volume>
<fpage>1363</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="pmid">23707776</pub-id>
</element-citation>
</ref>
<ref id="R127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geschwind</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>A human cerebral deconnection syndrome. A preliminary report.</article-title>
<source/>Neurology
          <year>1962</year>
<volume>12</volume>
<fpage>675</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="pmid">13898109</pub-id>
</element-citation>
</ref>
<ref id="R128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dell'acqua</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Thiebaut de Schotten</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A revised limbic system model for memory, emotion and behavior.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2013</year>
<volume>37</volume>
<fpage>1724</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="pmid">23850593</pub-id>
</element-citation>
</ref>
<ref id="R129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dahlstrom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoistad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marcellino</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jansson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission.</article-title>
<source/>Brain Res. Brain Res. Rev.
          <year>2007</year>
<volume>55</volume>
<fpage>17</fpage>
<lpage>54</lpage>
</element-citation>
</ref>
<ref id="R130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sluimer</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>van der Flier</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Karas</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Scheltens</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Barkhof</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wholebrain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients.</article-title>
<source/>Radiology
          <year>2008</year>
<volume>248</volume>
<fpage>590</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="pmid">18574133</pub-id>
</element-citation>
</ref>
<ref id="R131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Whitwell</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study.</article-title>
<source/>Lancet
          <year>2003</year>
<volume>362</volume>
<fpage>1121</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="pmid">14550701</pub-id>
</element-citation>
</ref>
<ref id="R132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>de Zubicaray</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Janke</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Semple</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dynamics of gray matter loss in Alzheimer's disease.</article-title>
<source/>J. Neurosci.
          <year>2003</year>
<volume>23</volume>
<fpage>994</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="pmid">12574429</pub-id>
</element-citation>
</ref>
<ref id="R133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ridha</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Godbolt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pepple</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>M.N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.</article-title>
<source/>Lancet Neurol.
          <year>2006</year>
<volume>5</volume>
<fpage>828</fpage>
<lpage>834</lpage>
<pub-id pub-id-type="pmid">16987729</pub-id>
</element-citation>
</ref>
<ref id="R134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Chertkow</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lerch</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Dorr</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Kabani</surname>
<given-names>N.J.</given-names>
</name>
</person-group>
<article-title>Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease.</article-title>
<source/>Brain
          <year>2006</year>
<volume>129</volume>
<fpage>2885</fpage>
<lpage>2893</lpage>
<pub-id pub-id-type="pmid">17008332</pub-id>
</element-citation>
</ref>
<ref id="R135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonald</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Gharapetian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fennema-Notestine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hagler</surname>
<given-names>D.J.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Holland</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
<collab>Alzheimer's Disease Neuroimaging Initiative</collab>
</person-group>
<article-title>Regional rates of neocortical atrophy from normal aging to early Alzheimer disease.</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<fpage>457</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">19667321</pub-id>
</element-citation>
</ref>
<ref id="R136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Zivkovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Psychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer's disease.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2001</year>
<volume>13</volume>
<fpage>56</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">11207330</pub-id>
</element-citation>
</ref>
<ref id="R137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ball</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Huppert</surname>
<given-names>F.A.</given-names>
</name>
</person-group>
<article-title>Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits.</article-title>
<source/>J. Intellect. Disabil. Res.
          <year>2010</year>
<volume>54</volume>
<fpage>320</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">20202073</pub-id>
</element-citation>
</ref>
<ref id="R138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peavy</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Edland</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and “pure” Alzheimer disease.</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2013</year>
<volume>21</volume>
<fpage>509</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="pmid">23567425</pub-id>
</element-citation>
</ref>
<ref id="R139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minoshima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giordani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berent</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Kuhl</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease.</article-title>
<source/>Ann. Neurol.
          <year>1997</year>
<volume>42</volume>
<fpage>85</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">9225689</pub-id>
</element-citation>
</ref>
<ref id="R140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckner</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>LaRossa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fotenos</surname>
<given-names>A.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory.</article-title>
<source/>J. Neurosci.
          <year>2005</year>
<volume>25</volume>
<fpage>7709</fpage>
<lpage>7717</lpage>
<pub-id pub-id-type="pmid">16120771</pub-id>
</element-citation>
</ref>
<ref id="R141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broyd</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Demanuele</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Debener</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Helps</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Sonuga-Barke</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Default-mode brain dysfunction in mental disorders: a systematic review.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2009</year>
<volume>33</volume>
<fpage>279</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="pmid">18824195</pub-id>
</element-citation>
</ref>
<ref id="R142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Greicius</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Gennatas</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Growdon</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Rabinovici</surname>
<given-names>G.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<fpage>1352</fpage>
<lpage>1367</lpage>
<pub-id pub-id-type="pmid">20410145</pub-id>
</element-citation>
</ref>
<ref id="R143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mormino</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Madison</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayenga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Smiljic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jagust</surname>
<given-names>W.J.</given-names>
</name>
</person-group>
<article-title>β-Amyloid affects frontal and posterior brain networks in normal aging.</article-title>
<source/>Neuroimage
          <year>2011</year>
<volume>54</volume>
<fpage>1887</fpage>
<lpage>1895</lpage>
<pub-id pub-id-type="pmid">20965254</pub-id>
</element-citation>
</ref>
<ref id="R144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wilcock</surname>
<given-names>G.K.</given-names>
</name>
</person-group>
<article-title>The cholinergic hypothesis of Alzheimer's disease: a review of progress.</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>1999</year>
<volume>66</volume>
<fpage>137</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">10071091</pub-id>
</element-citation>
</ref>
<ref id="R145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenk</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>Neuropathologic changes in Alzheimer’s disease.</article-title>
<source/>J. Clin. Psychiatry
          <year>2003</year>
<volume>64</volume>
<fpage>7</fpage>
<lpage>10</lpage>
</element-citation>
</ref>
<ref id="R146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvizi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van Hoesen</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Damasio</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The selective vulnerability of brainstem nuclei to Alzheimer’s disease.</article-title>
<source/>Ann. Neurol.
          <year>2001</year>
<volume>49</volume>
<fpage>53</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">11198297</pub-id>
</element-citation>
</ref>
<ref id="R147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starkstein</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Mizrahi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Depression in Alzheimer's disease.</article-title>
<source/>Expert Rev. Neurother.
          <year>2006</year>
<volume>6</volume>
<fpage>887</fpage>
<lpage>895</lpage>
<pub-id pub-id-type="pmid">16784411</pub-id>
</element-citation>
</ref>
<ref id="R148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Mussele</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bekelaar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Le Bastard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vermeiren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Saerens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2013</year>
<volume>28</volume>
<fpage>947</fpage>
<lpage>958</lpage>
<pub-id pub-id-type="pmid">23255479</pub-id>
</element-citation>
</ref>
<ref id="R149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessing</surname>
<given-names>L.V.</given-names>
</name>
</person-group>
<article-title>Depression and the risk for dementia.</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2012</year>
<volume>25</volume>
<fpage>457</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="pmid">22801361</pub-id>
</element-citation>
</ref>
<ref id="R150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballmaier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sowell</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Narr</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Lavretsky</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mapping brain size and cortical gray matter changes in elderly depression.</article-title>
<source/>Biol. Psychiatry
          <year>2004</year>
<volume>55</volume>
<fpage>382</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="pmid">14960291</pub-id>
</element-citation>
</ref>
<ref id="R151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nahmias</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>MacQueen</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Lower hippocampal volume in patients suffering from depression: a meta-analysis.</article-title>
<source/>Am. J. Psychiatry
          <year>2004</year>
<volume>161</volume>
<fpage>598</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="pmid">15056502</pub-id>
</element-citation>
</ref>
<ref id="R152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schocke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Auffinger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Esterhammer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry.</article-title>
<source/>Psychiatry Res.
          <year>2008</year>
<volume>164</volume>
<fpage>237</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="pmid">19013058</pub-id>
</element-citation>
</ref>
<ref id="R153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions.</article-title>
<source/>Biol. Psychiatry
          <year>2012</year>
<volume>71</volume>
<fpage>814</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="pmid">22322105</pub-id>
</element-citation>
</ref>
<ref id="R154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahodne</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Gongvatana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Tremont</surname>
<given-names>G.</given-names>
</name>
<collab>Alzheimer's Disease Neuroimaging Initiative</collab>
</person-group>
<article-title>Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment?</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2013</year>
<volume>21</volume>
<fpage>1098</fpage>
<lpage>1106</lpage>
<pub-id pub-id-type="pmid">23636003</pub-id>
</element-citation>
</ref>
<ref id="R155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Royall</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>R.F.</given-names>
</name>
</person-group>
<article-title>Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline.</article-title>
<source/>Alzheimers Dement.
          <year>2013</year>
<volume>9</volume>
<fpage>318</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="pmid">23154050</pub-id>
</element-citation>
</ref>
<ref id="R156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Royall</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Vidoni</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Honea</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>The default mode network may be the key substrate of depressive symptom-related cognitive changes.</article-title>
<source/>J. Alzheimers Dis.
          <year>2013</year>
<volume>34</volume>
<fpage>547</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="pmid">23254633</pub-id>
</element-citation>
</ref>
<ref id="R157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Abnormal functional connectivity of the default mode network in remitted late-onset depression.</article-title>
<source/>J. Affect. Disord.
          <year>2013</year>
<volume>147</volume>
<fpage>277</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">23270974</pub-id>
</element-citation>
</ref>
<ref id="R158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munro</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Guercio</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Wigman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Amariglio</surname>
<given-names>R.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment.</article-title>
<source/>J. Alzheimers Dis.
          <year>2015</year>
<volume>46</volume>
<fpage>727</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="pmid">25854929</pub-id>
</element-citation>
</ref>
<ref id="R159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapp</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Schnaider-Beeri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perl</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Purohit</surname>
<given-names>D.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>161</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="pmid">16461859</pub-id>
</element-citation>
</ref>
<ref id="R160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klatka</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Schiffer</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups.</article-title>
<source/>Neurology
          <year>1996</year>
<volume>47</volume>
<fpage>1148</fpage>
<lpage>1152</lpage>
<pub-id pub-id-type="pmid">8909420</pub-id>
</element-citation>
</ref>
<ref id="R161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rubio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schiffer</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Lewy body disease: can we diagnose it?</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>1998</year>
<volume>10</volume>
<fpage>405</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">9813785</pub-id>
</element-citation>
</ref>
<ref id="R162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McKeith</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Neill</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease.</article-title>
<source/>Am. J. Psychiatry
          <year>1999</year>
<volume>156</volume>
<fpage>1039</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="pmid">10401449</pub-id>
</element-citation>
</ref>
<ref id="R163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fritze</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ehrt</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hortobagyi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Depressive symptoms in Alzheimer’s disease and Lewy body dementia: a one-year follow-up study.</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2011</year>
<volume>32</volume>
<fpage>143</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">21986003</pub-id>
</element-citation>
</ref>
<ref id="R164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaufer</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies.</article-title>
<source/>Neurology
          <year>2000</year>
<volume>54</volume>
<fpage>1780</fpage>
<lpage>1787</lpage>
<pub-id pub-id-type="pmid">10802784</pub-id>
</element-citation>
</ref>
<ref id="R165">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Martin-Sanchez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease.</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<fpage>660</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="pmid">16924019</pub-id>
</element-citation>
</ref>
<ref id="R166">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drevets</surname>
<given-names>W.C.</given-names>
</name>
</person-group>
<article-title>Neuroimaging abnormalities in the amygdala in mood disorders.</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2003</year>
<volume>985</volume>
<fpage>420</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">12724175</pub-id>
</element-citation>
</ref>
<ref id="R167">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Mallory</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer’s disease.</article-title>
<source/>Neuroreport
          <year>1995</year>
<volume>6</volume>
<fpage>673</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="pmid">7605925</pub-id>
</element-citation>
</ref>
<ref id="R168">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uversky</surname>
<given-names>V.N.</given-names>
</name>
</person-group>
<article-title>Alpha-synuclein misfolding and neurodegenerative diseases.</article-title>
<source/>Curr. Protein Pept. Sci.
          <year>2008</year>
<volume>9</volume>
<fpage>507</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="pmid">18855701</pub-id>
</element-citation>
</ref>
<ref id="R169">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan-Palay</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Asan</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.</article-title>
<source/>J. Comp. Neurol.
          <year>1989</year>
<volume>287</volume>
<fpage>373</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="pmid">2570794</pub-id>
</element-citation>
</ref>
<ref id="R170">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Förstl</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luthert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lantos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Clinical and neuropathological correlates of depression in Alzheimer's disease.</article-title>
<source/>Psychol. Med.
          <year>1992</year>
<volume>22</volume>
<fpage>877</fpage>
<lpage>884</lpage>
<pub-id pub-id-type="pmid">1488485</pub-id>
</element-citation>
</ref>
<ref id="R171">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubenko</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Moossy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kopp</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Neurochemical correlates of major depression in primary dementia.</article-title>
<source/>Arch. Neurol.
          <year>1990</year>
<volume>47</volume>
<fpage>209</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">1689144</pub-id>
</element-citation>
</ref>
<ref id="R172">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermeiren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aerts</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease.</article-title>
<source/>Neurobiol. Aging
          <year>2014</year>
<volume>35</volume>
<fpage>2691</fpage>
<lpage>2700</lpage>
<pub-id pub-id-type="pmid">24997673</pub-id>
</element-citation>
</ref>
<ref id="R173">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermeiren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aerts</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.</article-title>
<source/>J. Alzheimers Dis.
          <year>2014</year>
<volume>41</volume>
<fpage>819</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="pmid">24685637</pub-id>
</element-citation>
</ref>
<ref id="R174">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Halloran</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Storey</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The cerebellum and neuropsychological functioning: A critical review.</article-title>
<source/>J. Clin. Exp. Neuropsychol.
          <year>2012</year>
<volume>34</volume>
<fpage>35</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">22047489</pub-id>
</element-citation>
</ref>
<ref id="R175">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goeb</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Even</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gohier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dubas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Garré</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Psychiatric side effects of interferon-beta in multiple sclerosis.</article-title>
<source/>Eur. Psychiatry
          <year>2006</year>
<volume>21</volume>
<fpage>186</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">16386408</pub-id>
</element-citation>
</ref>
<ref id="R176">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>André</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Szegedi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Lestage</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin.</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>13</volume>
<fpage>4200</fpage>
<lpage>4209</lpage>
</element-citation>
</ref>
<ref id="R177">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luiten</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Eisel</surname>
<given-names>U.L.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Alzheimer's disease and major depression.</article-title>
<source/>Biol. Psychiatry
          <year>2010</year>
<volume>67</volume>
<fpage>503</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="pmid">20185031</pub-id>
</element-citation>
</ref>
<ref id="R178">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naudé</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Nyakas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eiden</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Ait-Ali</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>van der Heide</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease.</article-title>
<source/>FASEB J.
          <year>2012</year>
<volume>26</volume>
<fpage>2811</fpage>
<lpage>2823</lpage>
<pub-id pub-id-type="pmid">22441986</pub-id>
</element-citation>
</ref>
<ref id="R179">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naudé</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Eisel</surname>
<given-names>U.L.</given-names>
</name>
<name>
<surname>Comijs</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Groenewold</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Bosker</surname>
<given-names>F.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression.</article-title>
<source/>J. Psychosom. Res.
          <year>2013</year>
<volume>75</volume>
<fpage>444</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="pmid">24182633</pub-id>
</element-citation>
</ref>
<ref id="R180">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naudé</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>den Boer</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Comijs</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Bosker</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Zuidersma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Groenewold</surname>
<given-names>N.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex-specific associations between Neutrophil Gelatinase-Associated Lipocalin (NGAL) and cognitive domains in late-life depression.</article-title>
<source/>Psychoneuroendocrinology
          <year>2014</year>
<volume>48</volume>
<fpage>169</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">25019974</pub-id>
</element-citation>
</ref>
<ref id="R181">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naudé</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Coppus</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Vermeiren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Eisel</surname>
<given-names>U.L.</given-names>
</name>
<name>
<surname>van Duijn</surname>
<given-names>C.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.</article-title>
<source/>J. Alzheimers Dis.
          <year>2015</year>
<volume>45</volume>
<fpage>733</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="pmid">25613101</pub-id>
</element-citation>
</ref>
<ref id="R182">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donnemiller</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Heilmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wenning</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Decristoforo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moncayo</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.</article-title>
<source/>Eur. J. Nucl. Med.
          <year>1997</year>
<volume>24</volume>
<fpage>320</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="pmid">9143472</pub-id>
</element-citation>
</ref>
<ref id="R183">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirono</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ikejiri</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimomura</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frontal lobe hypometabolism and depression in Alzheimer's disease.</article-title>
<source/>Neurology
          <year>1998</year>
<volume>50</volume>
<fpage>380</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="pmid">9484357</pub-id>
</element-citation>
</ref>
<ref id="R184">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy-Cooperman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Burhan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Rafi-Tari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kusano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease.</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2008</year>
<volume>33</volume>
<fpage>218</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">18592038</pub-id>
</element-citation>
</ref>
<ref id="R185">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caroli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Geroldi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Barnden</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>U.P.</given-names>
</name>
<name>
<surname>Bonetti</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional compensation in incipient Alzheimer's disease.</article-title>
<source/>Neurobiol. Aging
          <year>2010</year>
<volume>31</volume>
<fpage>387</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="pmid">18554752</pub-id>
</element-citation>
</ref>
<ref id="R186">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kataoka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kawabe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Higashiyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT.</article-title>
<source/>Psychiatry Clin. Neurosci.
          <year>2010</year>
<volume>64</volume>
<fpage>293</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="pmid">20602729</pub-id>
</element-citation>
</ref>
<ref id="R187">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedrosa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Teixeira-Sousa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bastos-Leite</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Early-onset Alzheimer disease: the contribution of neuroimaging for the diagnosis.</article-title>
<source/>Psychiatry Res.
          <year>2010</year>
<volume>182</volume>
<fpage>287</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">20488678</pub-id>
</element-citation>
</ref>
<ref id="R188">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starkstein</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Mizrahi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Capizzano</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Acion</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brockman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Power</surname>
<given-names>B.D.</given-names>
</name>
</person-group>
<article-title>Neuroimaging correlates of apathy and depression in Alzheimer's disease.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2009</year>
<volume>21</volume>
<fpage>259</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="pmid">19776304</pub-id>
</element-citation>
</ref>
<ref id="R189">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendricksen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ferrier</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression.</article-title>
<source/>Am. J. Psychiatry
          <year>2004</year>
<volume>161</volume>
<fpage>1096</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="pmid">15169699</pub-id>
</element-citation>
</ref>
<ref id="R190">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Alder</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Presynaptic serotonergic markers in community-acquired cases of Alzheimer’s disease: correlations with depression and neuroleptic medication.</article-title>
<source/>J. Neurochem.
          <year>1996</year>
<volume>66</volume>
<fpage>1592</fpage>
<lpage>1598</lpage>
<pub-id pub-id-type="pmid">8627315</pub-id>
</element-citation>
</ref>
<ref id="R191">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piggott</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rowan</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies.</article-title>
<source/>J. Affect. Disord.
          <year>2002</year>
<volume>69</volume>
<fpage>219</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">12103469</pub-id>
</element-citation>
</ref>
<ref id="R192">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2011</year>
<volume>213</volume>
<fpage>431</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="pmid">20625884</pub-id>
</element-citation>
</ref>
<ref id="R193">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pace</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tempesta</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lavecchia</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Macheda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bedse</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease.</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2014</year>
<volume>18</volume>
<fpage>pyu020</fpage>
<pub-id pub-id-type="pmid">25609597</pub-id>
</element-citation>
</ref>
<ref id="R194">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tagariello</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Amore</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Depression and apathy in dementia: same syndrome or different constructs? A critical review.</article-title>
<source/>Arch. Gerontol. Geriatr.
          <year>2009</year>
<volume>49</volume>
<fpage>246</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">19022508</pub-id>
</element-citation>
</ref>
<ref id="R195">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPherson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tiken</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Back-Madruga</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Apathy and executive function in Alzheimer’s disease.</article-title>
<source/>J. Int. Neuropsychol. Soc.
          <year>2002</year>
<volume>8</volume>
<fpage>373</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="pmid">11939696</pub-id>
</element-citation>
</ref>
<ref id="R196">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakaaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shinagawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hongo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tatsumi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Association between apathy/depression and executive function in patients with Alzheimer’s disease.</article-title>
<source/>Int. Psychogeriatr.
          <year>2008</year>
<volume>20</volume>
<fpage>964</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="pmid">18462557</pub-id>
</element-citation>
</ref>
<ref id="R197">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marin</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Apathy: a neuropsychiatric syndrome.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>1991</year>
<volume>3</volume>
<fpage>243</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">1821241</pub-id>
</element-citation>
</ref>
<ref id="R198">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Masterman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>A.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Apathy is not depression.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>1998</year>
<volume>10</volume>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="pmid">9706539</pub-id>
</element-citation>
</ref>
<ref id="R199">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krogstad</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Finset</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity.</article-title>
<source/>Psychol. Med.
          <year>1999</year>
<volume>29</volume>
<fpage>447</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="pmid">10218936</pub-id>
</element-citation>
</ref>
<ref id="R200">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnhart</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Makela</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Latocha</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>SSRI-induced apathy syndrome:a clinical review.</article-title>
<source/>J. Psychiatr. Pract.
          <year>2004</year>
<volume>10</volume>
<fpage>196</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">15330228</pub-id>
</element-citation>
</ref>
<ref id="R201">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guimarães</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Beato</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Caramelli</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Neurobiology of apathy in Alzheimer's disease.</article-title>
<source/>Arq. Neuropsiquiatr.
          <year>2008</year>
<volume>66</volume>
<fpage>436</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="pmid">18641892</pub-id>
</element-citation>
</ref>
<ref id="R202">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Tranel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Damasio</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Van Hoesen</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>The autonomic-related cortex: pathology in Alzheimer’s disease.</article-title>
<source/>Cereb. Cortex
          <year>1997</year>
<volume>7</volume>
<fpage>86</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">9023436</pub-id>
</element-citation>
</ref>
<ref id="R203">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Tekin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>H.V.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Neuropathological correlates of apathy in Alzheimer’s disease.</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2006</year>
<volume>21</volume>
<fpage>144</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">16391476</pub-id>
</element-citation>
</ref>
<ref id="R204">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mintun</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Larossa</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Sheline</surname>
<given-names>Y.I.</given-names>
</name>
<name>
<surname>Dence</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Mach</surname>
<given-names>R.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<fpage>446</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">16894106</pub-id>
</element-citation>
</ref>
<ref id="R205">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tekin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mega</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Masterman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Garakian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>H.V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease.</article-title>
<source/>Ann. Neurol.
          <year>2001</year>
<volume>49</volume>
<fpage>355</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="pmid">11261510</pub-id>
</element-citation>
</ref>
<ref id="R206">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruen</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>McGeown</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Shanks</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Venneri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease.</article-title>
<source/>Brain
          <year>2008</year>
<volume>131</volume>
<fpage>2455</fpage>
<lpage>2463</lpage>
<pub-id pub-id-type="pmid">18669506</pub-id>
</element-citation>
</ref>
<ref id="R207">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tunnard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hurt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wahlund</surname>
<given-names>L.O.</given-names>
</name>
<name>
<surname>Mecocci</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tsolaki</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Apathy and cortical atrophy in Alzheimer's disease.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2011</year>
<volume>26</volume>
<fpage>741</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="pmid">20872914</pub-id>
</element-citation>
</ref>
<ref id="R208">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craig</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Itti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebral blood flow correlates of apathy in Alzheimer disease.</article-title>
<source/>Arch. Neurol.
          <year>1996</year>
<volume>53</volume>
<fpage>1116</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="pmid">8912484</pub-id>
</element-citation>
</ref>
<ref id="R209">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migneco</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Benoît</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koulibaly</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Dygai</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bertogliati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Desvignes</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer’s disease and nondemented patients.</article-title>
<source/>Neuroimage
          <year>2001</year>
<volume>13</volume>
<fpage>896</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="pmid">11304085</pub-id>
</element-citation>
</ref>
<ref id="R210">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benoit</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koulibaly</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Migneco</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Darcourt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pringuey</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>P.H.</given-names>
</name>
</person-group>
<article-title>Brain perfusion in Alzheimer’s disease with and without apathy: a SPECT study with statistical parametric mapping analysis.</article-title>
<source/>Psychiatry Res.
          <year>2002</year>
<volume>114</volume>
<fpage>103</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="pmid">12036510</pub-id>
</element-citation>
</ref>
<ref id="R211">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lanctot</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease.</article-title>
<source/>CNS Neurosci. Ther.
          <year>2011</year>
<volume>17</volume>
<fpage>411</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="pmid">20560994</pub-id>
</element-citation>
</ref>
<ref id="R212">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martorana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Is dopamine involved in Alzheimer's disease?</article-title>
<source/>Front. Aging Neurosci.
          <year>2014</year>
<volume>25</volume>
<fpage>252</fpage>
</element-citation>
</ref>
<ref id="R213">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storga</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vrecko</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Birkmayer</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Reibnegger</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients.</article-title>
<source/>Neurosci. Lett.
          <year>1996</year>
<volume>203</volume>
<fpage>29</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">8742039</pub-id>
</element-citation>
</ref>
<ref id="R214">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kosaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iiziku</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.</article-title>
<source/>J. Neurochem.
          <year>1984</year>
<volume>43</volume>
<fpage>388</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="pmid">6204013</pub-id>
</element-citation>
</ref>
<ref id="R215">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nazarali</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>G.P.</given-names>
</name>
</person-group>
<article-title>Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer’s disease: A postmortem study.</article-title>
<source/>Cell. Mol. Neurobiol.
          <year>1992</year>
<volume>12</volume>
<fpage>581</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="pmid">1283363</pub-id>
</element-citation>
</ref>
<ref id="R216">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cross</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Crow</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Ferrier</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Markakis</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Striatal dopamine receptors in Alzheimer-type dementia.</article-title>
<source/>Neurosci. Lett.
          <year>1984</year>
<volume>52</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">6241300</pub-id>
</element-citation>
</ref>
<ref id="R217">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Keyser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ebinger</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vauquelin</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer’s disease.</article-title>
<source/>Arch. Neurol.
          <year>1990</year>
<volume>47</volume>
<fpage>761</fpage>
<lpage>763</lpage>
<pub-id pub-id-type="pmid">2357156</pub-id>
</element-citation>
</ref>
<ref id="R218">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Henteleff</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>B.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.</article-title>
<source/>Arch. Neurol.
          <year>2001</year>
<volume>58</volume>
<fpage>466</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="pmid">11255451</pub-id>
</element-citation>
</ref>
<ref id="R219">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lanctôt</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.</article-title>
<source/>Ageing Res. Rev.
          <year>2011</year>
<volume>10</volume>
<fpage>404</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">21292041</pub-id>
</element-citation>
</ref>
<ref id="R220">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drijgers</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Aalten</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Winogrodzka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verhey</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Leentjens</surname>
<given-names>A.F.</given-names>
</name>
</person-group>
<article-title>Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review.</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2009</year>
<volume>28</volume>
<fpage>13</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">19609082</pub-id>
</element-citation>
</ref>
<ref id="R221">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zandi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Welsh-Bohmer</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>M.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2008</year>
<volume>23</volume>
<fpage>170</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">17607801</pub-id>
</element-citation>
</ref>
<ref id="R222">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Agitation and aggression in people with Alzheimer's disease.</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2013</year>
<volume>26</volume>
<fpage>252</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">23528917</pub-id>
</element-citation>
</ref>
<ref id="R223">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavretsky</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2008</year>
<volume>16</volume>
<fpage>523</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="pmid">18591572</pub-id>
</element-citation>
</ref>
<ref id="R224">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthews</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Minger</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.T.</given-names>
</name>
</person-group>
<article-title>Noradrenergic changes, aggressive behavior, and cognition in patients with dementia.</article-title>
<source/>Biol. Psychiatry
          <year>2002</year>
<volume>51</volume>
<fpage>407</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="pmid">11904135</pub-id>
</element-citation>
</ref>
<ref id="R225">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia.</article-title>
<source/>Neuroreport
          <year>2010</year>
<volume>21</volume>
<fpage>1111</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="pmid">20890229</pub-id>
</element-citation>
</ref>
<ref id="R226">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirono</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mega</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Dinov</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Mishkin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Left frontotemporal hypoperfusion is associated with aggression in patients with dementia.</article-title>
<source/>Arch. Neurol.
          <year>2000</year>
<volume>57</volume>
<fpage>861</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="pmid">10867784</pub-id>
</element-citation>
</ref>
<ref id="R227">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancôt</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nadkarni</surname>
<given-names>N.K.</given-names>
</name>
<name>
<surname>Leibovitch</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Medial temporal hypoperfusion and aggression in Alzheimer’s disease.</article-title>
<source/>Arch. Neurol.
          <year>2004</year>
<volume>61</volume>
<fpage>1731</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="pmid">15534184</pub-id>
</element-citation>
</ref>
<ref id="R228">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulin</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Dautoff</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>B.C.</given-names>
</name>
<collab>Alzheimer's Disease Neuroimaging Initiative</collab>
</person-group>
<article-title>Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity.</article-title>
<source/>Psychiatry Res.
          <year>2011</year>
<volume>194</volume>
<fpage>7</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">21920712</pub-id>
</element-citation>
</ref>
<ref id="R229">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trzepacz</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bhamidipati</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Willis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Forrester</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tabas</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.</article-title>
<source/>Alzheimers Dement.
          <year>2013</year>
<volume>9</volume>
<fpage>S95</fpage>
<lpage>S104</lpage>
<pub-id pub-id-type="pmid">23253778</pub-id>
</element-citation>
</ref>
<ref id="R230">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minger</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholinergic deficits contribute to behavioral disturbance in patients with dementia.</article-title>
<source/>Neurology
          <year>2000</year>
<volume>55</volume>
<fpage>1460</fpage>
<lpage>1467</lpage>
<pub-id pub-id-type="pmid">11094098</pub-id>
</element-citation>
</ref>
<ref id="R231">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Alloza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gil-Bea</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Diez-Ariza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Lasheras</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.</article-title>
<source/>Neuropsychologia
          <year>2005</year>
<volume>43</volume>
<fpage>442</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="pmid">15707619</pub-id>
</element-citation>
</ref>
<ref id="R232">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rabheru</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2005</year>
<volume>13</volume>
<issue>6</issue>
<fpage>527</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">15956273</pub-id>
</element-citation>
</ref>
<ref id="R233">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>McRae</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<collab>Donepezil-Sertraline Study Group</collab>
</person-group>
<article-title>Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2006</year>
<volume>14</volume>
<fpage>605</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="pmid">16816014</pub-id>
</element-citation>
</ref>
<ref id="R234">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Stratmann</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Procter</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease.</article-title>
<source/>Ann. Neurol.
          <year>1988</year>
<volume>23</volume>
<fpage>616</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="pmid">2457353</pub-id>
</element-citation>
</ref>
<ref id="R235">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanctôt</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eryavec</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>van Reekum</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Naranjo</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Central serotonergic activity is related to the aggressive behaviors of Alzheimer's disease.</article-title>
<source/>Neuropsychopharmacology
          <year>2002</year>
<volume>27</volume>
<fpage>646</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="pmid">12377401</pub-id>
</element-citation>
</ref>
<ref id="R236">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ueki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shinjo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease.</article-title>
<source/>J. Alzheimers Dis.
          <year>2007</year>
<volume>12</volume>
<fpage>245</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="pmid">18057558</pub-id>
</element-citation>
</ref>
<ref id="R237">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweet</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Sukonick</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Mulsant</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Klunk</surname>
<given-names>W.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease.</article-title>
<source/>Int. Psychogeriatr.
          <year>2001</year>
<volume>13</volume>
<fpage>401</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="pmid">12003247</pub-id>
</element-citation>
</ref>
<ref id="R238">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo-Neustadt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zomorodian</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Preserved cerebellar tyrosine hydroxylase-immunoreactive neuronal fibers in a behaviorally aggressive subgroup of Alzheimer’s disease patients.</article-title>
<source/>Neuroscience
          <year>1998</year>
<volume>87</volume>
<fpage>55</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">9722141</pub-id>
</element-citation>
</ref>
<ref id="R239">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snaith</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Zigmond</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>The hospital anxiety and depression scale.</article-title>
<source/>Br. Med. J. (Clin. Res. Ed.)
          <year>1986</year>
<volume>292</volume>
<fpage>344</fpage>
</element-citation>
</ref>
<ref id="R240">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tschanz</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Steffens</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Breitner</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.</article-title>
<source/>Am. J. Psychiatry
          <year>2000</year>
<volume>157</volume>
<fpage>708</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="pmid">10784462</pub-id>
</element-citation>
</ref>
<ref id="R241">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maertens</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nagels</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vloeberghs</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mariën</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Symons</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2005</year>
<volume>20</volume>
<fpage>1028</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="pmid">16250064</pub-id>
</element-citation>
</ref>
<ref id="R242">
<label>242</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Monserratt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Feil</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Harwood</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mandelkern</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anxiety and regional cortical glucose metabolism in patients with Alzheimer's disease.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2006</year>
<volume>18</volume>
<fpage>521</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">17135378</pub-id>
</element-citation>
</ref>
<ref id="R243">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beauquis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vinuesa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pomilio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pavía</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Galván</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Saravia</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer's disease.</article-title>
<source/>Hippocampus
          <year>2014</year>
<volume>24</volume>
<fpage>257</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">24132937</pub-id>
</element-citation>
</ref>
<ref id="R244">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeste</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>S.I.</given-names>
</name>
</person-group>
<article-title>Psychosis of alzheimer's disease and related dementias. diagnostic criteria for a distinct syndrome.</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2000</year>
<volume>8</volume>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">10648292</pub-id>
</element-citation>
</ref>
<ref id="R245">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Förstl</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Besthorn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Geiger-Kabisch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sattel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Delusional misidentification in Alzheimer's disease: a summary of clinical and biological aspects.</article-title>
<source/>Psychopathology
          <year>1994</year>
<volume>27</volume>
<fpage>194</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">7846237</pub-id>
</element-citation>
</ref>
<ref id="R246">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farber</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Newcomer</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Kinscherf</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2000</year>
<volume>57</volume>
<fpage>1165</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="pmid">11115331</pub-id>
</element-citation>
</ref>
<ref id="R247">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Jacoby</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Del Ser</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies.</article-title>
<source/>Am. J. Psychiatry
          <year>2004</year>
<volume>161</volume>
<fpage>843</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="pmid">15121649</pub-id>
</element-citation>
</ref>
<ref id="R248">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McShane</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gedling</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Reading</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease.</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>1995</year>
<volume>59</volume>
<fpage>185</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">7629537</pub-id>
</element-citation>
</ref>
<ref id="R249">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holroyd</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Downs</surname>
<given-names>J.H.</given-names>
<suffix>III</suffix>
</name>
</person-group>
<article-title>Occipital atrophy is associated with visual hallucinations in Alzheimer's disease.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2000</year>
<volume>12</volume>
<fpage>25</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">10678508</pub-id>
</element-citation>
</ref>
<ref id="R250">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>The occipital white matter lesions in Alzheimer's disease patients with visual hallucinations.</article-title>
<source/>Clin. Imaging
          <year>2006</year>
<volume>30</volume>
<fpage>388</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="pmid">17101407</pub-id>
</element-citation>
</ref>
<ref id="R251">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serra</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Perri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cercignani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spanò</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fadda</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Are the behavioral symptoms of Alzheimer’s disease directly associated with neurodegeneration?</article-title>
<source/>J. Alzheimers Dis.
          <year>2010</year>
<volume>21</volume>
<fpage>627</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="pmid">20555138</pub-id>
</element-citation>
</ref>
<ref id="R252">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Förstl</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease.</article-title>
<source/>Br. J. Psychiatry
          <year>1994</year>
<volume>165</volume>
<fpage>53</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">7953058</pub-id>
</element-citation>
</ref>
<ref id="R253">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Choo</surname>
<given-names>I.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Jhoo</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>U.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>vWhite matter changes associated with psychotic symptoms in Alzheimer’s disease patients.</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2006</year>
<volume>18</volume>
<fpage>191</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">16720796</pub-id>
</element-citation>
</ref>
<ref id="R254">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubenko</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Moossy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Claassen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kopp</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Neuropathologic and neurochemical correlates of psychosis in primary dementia.</article-title>
<source/>Arch. Neurol.
          <year>1991</year>
<volume>48</volume>
<fpage>619</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="pmid">1710105</pub-id>
</element-citation>
</ref>
<ref id="R255">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>O.F.</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex.</article-title>
<source/>Neurology
          <year>2001</year>
<volume>57</volume>
<fpage>805</fpage>
<lpage>811</lpage>
<pub-id pub-id-type="pmid">11552008</pub-id>
</element-citation>
</ref>
<ref id="R256">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koumaras</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gunay</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mirski</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer’s disease: results of a 52-week open-label study.</article-title>
<source/>Clin. Drug Investig.
          <year>2005</year>
<volume>2</volume>
<fpage>507</fpage>
<lpage>515</lpage>
</element-citation>
</ref>
<ref id="R257">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermeiren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aerts</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.</article-title>
<source/>Alzheimers Res. Ther.
          <year>2015</year>
<volume>7</volume>
<fpage>7</fpage>
<pub-id pub-id-type="pmid">25717350</pub-id>
</element-citation>
</ref>
<ref id="R258">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mega</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dinov</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Mishkin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Toga</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Cerebral correlates of psychotic symptoms in Alzheimer’s disease.</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2000</year>
<volume>69</volume>
<fpage>167</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="pmid">10896687</pub-id>
</element-citation>
</ref>
<ref id="R259">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staff</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Shanks</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Macintosh</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pestell</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Gemmell</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Venneri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Delusions in Alzheimer’s disease: SPET evidence of right hemispheric dysfunction.</article-title>
<source/>Cortex
          <year>1999</year>
<volume>35</volume>
<fpage>549</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="pmid">10574080</pub-id>
</element-citation>
</ref>
<ref id="R260">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geroldi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bresciani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zanetti</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>G.B.</given-names>
</name>
</person-group>
<article-title>Regional brain atrophy in patients with mild Alzheimer's disease and delusions.</article-title>
<source/>Int. Psychogeriatr.
          <year>2002</year>
<volume>14</volume>
<fpage>365</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">12670058</pub-id>
</element-citation>
</ref>
<ref id="R261">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mentis</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McIntosh</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Pietrini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>G.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease.</article-title>
<source/>Biol. Psychiatry
          <year>1995</year>
<volume>38</volume>
<fpage>438</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="pmid">8672604</pub-id>
</element-citation>
</ref>
<ref id="R262">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bajulaiye</surname>
<given-names>O.I.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>C.F.</given-names>
<suffix>III</suffix>
</name>
</person-group>
<article-title>Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates.</article-title>
<source/>Neurology
          <year>1991</year>
<volume>41</volume>
<fpage>906</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="pmid">2046938</pub-id>
</element-citation>
</ref>
<ref id="R263">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards-Lee</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leuchter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Quantitative electroencephalographic correlates of psychosis in Alzheimer disease.</article-title>
<source/>Neuropsychiatry Neuropsychol. Behav. Neurol.
          <year>2000</year>
<volume>13</volume>
<fpage>163</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">10910086</pub-id>
</element-citation>
</ref>
<ref id="R264">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Living by the clock: The circadian pacemaker in older people.</article-title>
<source/>Ageing Res. Rev.
          <year>2006</year>
<volume>5</volume>
<fpage>33</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">16126012</pub-id>
</element-citation>
</ref>
<ref id="R265">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coogan</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Schutová</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Husung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Furczyk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Baune</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Kropp</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The circadian system in Alzheimer's disease: disturbances, mechanisms, and opportunities.</article-title>
<source/>Biol. Psychiatry
          <year>2013</year>
<volume>74</volume>
<fpage>333</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="pmid">23273723</pub-id>
</element-citation>
</ref>
<ref id="R266">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bachman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rabins</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>“Sundowning” and other temporally associated agitation states in dementia patients.</article-title>
<source/>Annu. Rev. Med.
          <year>2006</year>
<volume>57</volume>
<fpage>499</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="pmid">16409163</pub-id>
</element-citation>
</ref>
<ref id="R267">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Vicentic</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Biological rhythms, higher brain function, and behavior: Gaps, opportunities, and challenges.</article-title>
<source/>Brain Res. Brain Res. Rev.
          <year>2009</year>
<volume>62</volume>
<fpage>57</fpage>
<lpage>70</lpage>
</element-citation>
</ref>
<ref id="R268">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Fliers</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Partiman</surname>
<given-names>T.S.</given-names>
</name>
</person-group>
<article-title>The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia.</article-title>
<source/>Brain Res.
          <year>1985</year>
<volume>342</volume>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">4041816</pub-id>
</element-citation>
</ref>
<ref id="R269">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stopa</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Volicer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kuo-Leblanc</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lathi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tate</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia.</article-title>
<source/>J. Neuropathol. Exp. Neurol.
          <year>1999</year>
<volume>58</volume>
<fpage>29</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">10068311</pub-id>
</element-citation>
</ref>
<ref id="R270">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>McLeland</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Toedebusch</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Duntley</surname>
<given-names>S.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep quality and preclinical Alzheimer disease.</article-title>
<source/>JAMA Neurol.
          <year>2013</year>
<volume>70</volume>
<fpage>587</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">23479184</pub-id>
</element-citation>
</ref>
<ref id="R271">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mander</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Saletin</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation.</article-title>
<source/>Nat. Neurosci.
          <year>2015</year>
<volume>18</volume>
<fpage>1051</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="pmid">26030850</pub-id>
</element-citation>
</ref>
<ref id="R272">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanecek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Mechanisms of melatonin action in the pituitary and SCN.</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>1999</year>
<volume>460</volume>
<fpage>191</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">10810514</pub-id>
</element-citation>
</ref>
<ref id="R273">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pappolla</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Chyan</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Poeggeler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frangione</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ghiso</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease.</article-title>
<source/>J. Neural Transm.
          <year>2000</year>
<volume>107</volume>
<fpage>203</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">10847561</pub-id>
</element-citation>
</ref>
<ref id="R274">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Kamphorst</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels.</article-title>
<source/>J. Pineal Res.
          <year>2003</year>
<volume>35</volume>
<fpage>125</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">12887656</pub-id>
</element-citation>
</ref>
<ref id="R275">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Feenstra</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Toranõ</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Van Kan</surname>
<given-names>H.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2003</year>
<volume>88</volume>
<fpage>5898</fpage>
<lpage>5906</lpage>
<pub-id pub-id-type="pmid">14671188</pub-id>
</element-citation>
</ref>
<ref id="R276">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisor</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Yesavage</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lapustea</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer’s disease: A role for cholinergic transmission.</article-title>
<source/>Neuroscience
          <year>2005</year>
<volume>131</volume>
<fpage>375</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="pmid">15708480</pub-id>
</element-citation>
</ref>
<ref id="R277">
<label>277</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuh</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia.</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2005</year>
<volume>76</volume>
<fpage>1337</fpage>
<lpage>1341</lpage>
<pub-id pub-id-type="pmid">16170072</pub-id>
</element-citation>
</ref>
<ref id="R278">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Ser</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hachinski</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Merskey</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Alzheimer's disease with and without cerebral infarcts.</article-title>
<source/>J. Neurol. Sci.
          <year>2005</year>
<volume>231</volume>
<fpage>3</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">15792814</pub-id>
</element-citation>
</ref>
<ref id="R279">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berlow</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Ellison</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Renshaw</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease.</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2010</year>
<volume>25</volume>
<fpage>780</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="pmid">19946864</pub-id>
</element-citation>
</ref>
<ref id="R280">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boeve</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Silber</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Ferman</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Benarroch</surname>
<given-names>E.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism.</article-title>
<source/>Neurology
          <year>2003</year>
<volume>61</volume>
<fpage>40</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">12847154</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig fig-type="figure" id="F1" position="float">
<label>Fig. (1)</label>
<caption>
<p>The accumulation of misfolded proteins in Alzheimer disease follows characteristic and predictable patterns as illustrated by the increasing intensity and spreading of color. (A) Amyloid plaques first appear in neocortex, followed by allocortex and finally progressing to subcortical regions. The three brain schemata reflect Montine A scores 1 – 3 from left to right. (B) Neurofibrillary tangles appear first in the allocortex of the medial temporal lobe and spreads to the associative isocortex, relatively sparing the primary sensory, motor, and visual areas. The three brain schemata reflect Montine B scores 1 – 3 from left to right. Reprinted with permission from [<xref ref-type="bibr" rid="R52">52</xref>].</p>
</caption>
<graphic xlink:href="CAR-13-1145_F1"></graphic>
</fig>
<fig fig-type="figure" id="F2" position="float">
<label>Fig. (2)</label>
<caption>
<p>At least three frontal-subcortical circuits mediate human behavior: (i) the dorsolateral prefrontal circuit mediating planning, organization, and executive function, (ii) the lateral orbitofrontal circuit mediating inhibitory control and (iii) the anterior cingulate circuit mediating motivated behavior. The prototypic structure of all circuits is an origin in the frontal lobes, projection to striatal structures, connections from striatum to globus pallidus and substantia nigra, projections from these two structures to specific thalamic nuclei, and a final link back to the frontal lobe. Indirect pathways projecting from striatum to globus pallidus externa, then to subthalamic nucleus, and back to the globus pallidus interna/substantia nigra, as well as connections of the substantia nigra and the subthalamic nucleus are not shown for. Legend: BA, Brodman area. Adapted from [<xref ref-type="bibr" rid="R124">124</xref>].</p>
</caption>
<graphic xlink:href="CAR-13-1145_F2"></graphic>
</fig>
<fig fig-type="figure" id="F3" position="float">
<label>Fig. (3)</label>
<caption>
<p>Illustration of a magnetic resonance imaging-based analysis technique to determine the pattern of cortical thinning (measure of cortical atrophy) as a function of disease progression. Age-matched control individuals, mild cognitive impairment (MCI) and Alzheimer’s disease (AD) groups were compared. Panel A: cortical thickness differences between the control and MCI group with the most significant difference seen in the (left) medial temporal region. Frontal and posterior parietal areas show differences in a more bilateral fashion. Panel B: Cortical thickness differences between the control and AD group clearly indicating bilateral medial and lateral temporal lobe differences are present bilaterally. Occipital, primary motor and primary sensory cortices show the least significant differences. Reprinted with permission from [<xref ref-type="bibr" rid="R134">134</xref>]. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment.</p>
</caption>
<graphic xlink:href="CAR-13-1145_F3"></graphic>
</fig>
<fig fig-type="figure" id="F4" position="float">
<label>Fig. (4)</label>
<caption>
<p>Neurochemical correlates of neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD). Scatter plots representing significant monoaminergic neurotransmitter correlates of NPS in the cerebellar cortex of autopsy-confirmed AD patients. Panel A: positive correlation between the DOPAC/DA ratio, indicative of DA turnover, and physically nonaggressive behavior (R=+0.497; p=0.003). Panel B: positive correlation between MHPG levels, the major noradrenergic metabolite, and affective disturbances (R=+0.562; p=0.0005). Panel C: positive correlation between the DOPAC/DA ratio and activity disturbances (R=+0.595; p=0.00026). Although the cerebellum has historically been considered to be a brain region principally involved in motor control and coordination, more recently, higher cognitive functions have been attributed to its physiological functions as well. A strong and sustained reciprocal connection between the deep cerebellar nuclei to the thalamus and then on to the (prefrontal) cerebral cortex, called cerebello-thalamic-cortical pathway, neuroanatomically accounts for the role of the cerebellum numerous behavioral processes. Cerebellar pathology and subsequent neurochemical alterations may underlie certain NPS. Abbreviations: AD, Alzheimer’s disease; Behave-AD, Behavioral Pathology in Alzheimer’s Disease Rating Scale; CMAI, Cohen-Mansfield Agitation Inventory; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol. Reprinted with permission from [<xref ref-type="bibr" rid="R173">173</xref>].</p>
</caption>
<graphic xlink:href="CAR-13-1145_F4"></graphic>
</fig>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Functional-anatomical division of the limbic system into three distinct but partially overlapping networks and corresponding functions and involvement in Alzheimer’s disease.</p>
</caption>
<table frame="border" rules="all" width="100%">
<thead>
<tr>
<th align="center" colspan="1" rowspan="2" scope="col" valign="top">
<bold>Limbic Network</bold>
</th>
<th align="center" colspan="1" rowspan="2" scope="col" valign="top">
<bold>Functions</bold>
</th>
<th align="center" colspan="2" rowspan="1" scope="colgroup" valign="top">
<bold>Relevance in Alzheimer’s Disease</bold>
</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" scope="colgroup" valign="top">
<bold>Disease Stage</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Related Symptomatology</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Hippocampal-diencephalic and<break></break>Parahippocampal-retrosplenial network</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Memory<break></break>• Spatial orientation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Early-stage AD<break></break>MCI</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Hippocampocentric memory dysfunction<break></break>• Anterograde and limited retrograde memory deficits<break></break>• Difficulties in spatial orientation</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Dorsomedial default network</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Attention<break></break>• Empathy<break></break>• Self-knowledge<break></break>• Mentalizing<break></break>• Response selection and action monitoring<break></break>• Person perception<break></break>• Autobiographical memory<break></break>• Pain perception</td>
<td align="center" colspan="1" rowspan="1" valign="top">Early-stage AD<break></break>MCI</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Disrupted episodic memory processing<break></break>• Disrupted goal-directed behaviors</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Temporo-amygdala-orbitofrontal network</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Behavioural inhibition<break></break>• Memory for temporally complex visual information<break></break>• Olfactory-gustatory-visceral functions<break></break>• Multimodal sensory integration<break></break>• Object reward association learning<break></break>• Outcome monitoring</td>
<td align="center" colspan="1" rowspan="1" valign="top">Advanced AD</td>
<td align="center" colspan="1" rowspan="1" valign="top">• Semantic deficits<break></break>• Language difficulties<break></break>• Personality changes<break></break>• NPS (e.g. aggression, disinhibition)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Legend: AD: Alzheimer’s disease; MCI: mild cognitive impairment; NPS: neuropsychiatric symptoms. Adapted from [<xref ref-type="bibr" rid="R128">128</xref>].</p>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>